US20040079702A1 - Method for anion-exchange adsorption and anion-exchangers - Google Patents
Method for anion-exchange adsorption and anion-exchangers Download PDFInfo
- Publication number
- US20040079702A1 US20040079702A1 US10/723,362 US72336203A US2004079702A1 US 20040079702 A1 US20040079702 A1 US 20040079702A1 US 72336203 A US72336203 A US 72336203A US 2004079702 A1 US2004079702 A1 US 2004079702A1
- Authority
- US
- United States
- Prior art keywords
- anion
- exchanger
- substance
- liquid
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 77
- 108091006522 Anion exchangers Proteins 0.000 title claims description 128
- 238000005349 anion exchange Methods 0.000 title claims description 35
- 238000001179 sorption measurement Methods 0.000 title claims description 33
- 239000003446 ligand Substances 0.000 claims abstract description 131
- 239000000126 substance Substances 0.000 claims abstract description 122
- 239000007788 liquid Substances 0.000 claims abstract description 91
- 239000011159 matrix material Substances 0.000 claims abstract description 74
- 125000006850 spacer group Chemical group 0.000 claims abstract description 69
- 238000003795 desorption Methods 0.000 claims abstract description 29
- 239000001257 hydrogen Substances 0.000 claims abstract description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 20
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 19
- 125000003118 aryl group Chemical group 0.000 claims abstract description 18
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 18
- 239000001301 oxygen Substances 0.000 claims abstract description 18
- 239000005864 Sulphur Substances 0.000 claims abstract description 15
- 150000003568 thioethers Chemical class 0.000 claims abstract description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 13
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 13
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 12
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 10
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000012216 screening Methods 0.000 claims abstract description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 44
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 40
- 125000004429 atom Chemical group 0.000 claims description 37
- -1 sulphone amides Chemical class 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 28
- 229910052757 nitrogen Inorganic materials 0.000 claims description 27
- 239000011780 sodium chloride Substances 0.000 claims description 22
- 239000000872 buffer Substances 0.000 claims description 20
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 17
- 229940098773 bovine serum albumin Drugs 0.000 claims description 17
- 230000003993 interaction Effects 0.000 claims description 16
- 238000010828 elution Methods 0.000 claims description 14
- 238000006467 substitution reaction Methods 0.000 claims description 14
- 235000018102 proteins Nutrition 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 239000012564 Q sepharose fast flow resin Substances 0.000 claims description 12
- 150000001408 amides Chemical class 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 102000006786 Chloride-Bicarbonate Antiporters Human genes 0.000 claims description 4
- 102000004407 Lactalbumin Human genes 0.000 claims description 4
- 108090000942 Lactalbumin Proteins 0.000 claims description 4
- 108091006260 SLC4A2 Proteins 0.000 claims description 4
- 102000012479 Serine Proteases Human genes 0.000 claims description 4
- 108010022999 Serine Proteases Proteins 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 108010026206 Conalbumin Proteins 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 101710162629 Trypsin inhibitor Proteins 0.000 claims description 3
- 229940122618 Trypsin inhibitor Drugs 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- 125000005647 linker group Chemical group 0.000 claims description 3
- 239000002753 trypsin inhibitor Substances 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 108010058846 Ovalbumin Proteins 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims description 2
- 239000003574 free electron Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 229940092253 ovalbumin Drugs 0.000 claims description 2
- JSPLKZUTYZBBKA-UHFFFAOYSA-N trioxidane Chemical class OOO JSPLKZUTYZBBKA-UHFFFAOYSA-N 0.000 claims description 2
- 235000021241 α-lactalbumin Nutrition 0.000 claims description 2
- 102000016955 Erythrocyte Anion Exchange Protein 1 Human genes 0.000 claims 1
- 108010014384 Erythrocyte Anion Exchange Protein 1 Proteins 0.000 claims 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims 1
- 238000011033 desalting Methods 0.000 abstract description 7
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 43
- 125000003277 amino group Chemical group 0.000 description 37
- 230000008878 coupling Effects 0.000 description 36
- 238000010168 coupling process Methods 0.000 description 36
- 238000005859 coupling reaction Methods 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 20
- 229960003151 mercaptamine Drugs 0.000 description 20
- 239000002585 base Substances 0.000 description 19
- 229920002684 Sepharose Polymers 0.000 description 18
- 239000012153 distilled water Substances 0.000 description 16
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000011084 recovery Methods 0.000 description 15
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 150000002430 hydrocarbons Chemical group 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000012488 sample solution Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- QHGUCRYDKWKLMG-QMMMGPOBSA-N (R)-octopamine Chemical compound NC[C@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-QMMMGPOBSA-N 0.000 description 5
- MVTRQRSNYWDWMY-UHFFFAOYSA-N 2-amino-4-(trifluoromethyl)benzenethiol Chemical compound NC1=CC(C(F)(F)F)=CC=C1S MVTRQRSNYWDWMY-UHFFFAOYSA-N 0.000 description 5
- DBLDQZASZZMNSL-QMMMGPOBSA-N 4-[(2s)-2-amino-3-hydroxypropyl]phenol Chemical compound OC[C@@H](N)CC1=CC=C(O)C=C1 DBLDQZASZZMNSL-QMMMGPOBSA-N 0.000 description 5
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 5
- QHGUCRYDKWKLMG-MRVPVSSYSA-N Octopamine Natural products NC[C@@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-MRVPVSSYSA-N 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 229960001576 octopamine Drugs 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229960004441 tyrosine Drugs 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229960005190 phenylalanine Drugs 0.000 description 4
- 150000003335 secondary amines Chemical group 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- STMDPCBYJCIZOD-UHFFFAOYSA-N 2-(2,4-dinitroanilino)-4-methylpentanoic acid Chemical compound CC(C)CC(C(O)=O)NC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O STMDPCBYJCIZOD-UHFFFAOYSA-N 0.000 description 3
- JWYUFVNJZUSCSM-UHFFFAOYSA-N 2-aminobenzimidazole Chemical compound C1=CC=C2NC(N)=NC2=C1 JWYUFVNJZUSCSM-UHFFFAOYSA-N 0.000 description 3
- WCDSVWRUXWCYFN-UHFFFAOYSA-N 4-aminobenzenethiol Chemical compound NC1=CC=C(S)C=C1 WCDSVWRUXWCYFN-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000003463 adsorbent Substances 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 230000003139 buffering effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 125000001453 quaternary ammonium group Chemical group 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- SWZCTMTWRHEBIN-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=C(O)C=C1 SWZCTMTWRHEBIN-QFIPXVFZSA-N 0.000 description 2
- UDQCRUSSQAXPJY-VIFPVBQESA-N (2s)-2-amino-3-(1h-indol-3-yl)propan-1-ol Chemical compound C1=CC=C2C(C[C@@H](CO)N)=CNC2=C1 UDQCRUSSQAXPJY-VIFPVBQESA-N 0.000 description 2
- AYMLQYFMYHISQO-QMMMGPOBSA-N (2s)-3-(1h-imidazol-3-ium-5-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CN=CN1 AYMLQYFMYHISQO-QMMMGPOBSA-N 0.000 description 2
- VUUSTLFFRIFAIC-YFKPBYRVSA-N (2s)-3-hydroxy-2-(thiophen-2-ylamino)propanoic acid Chemical compound OC[C@@H](C(O)=O)NC1=CC=CS1 VUUSTLFFRIFAIC-YFKPBYRVSA-N 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical class C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- ZQXIMYREBUZLPM-UHFFFAOYSA-N 1-aminoethanethiol Chemical compound CC(N)S ZQXIMYREBUZLPM-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JUCGVCVPNPBJIG-UHFFFAOYSA-N 2-amino-1-phenylpropane-1,3-diol Chemical compound OCC(N)C(O)C1=CC=CC=C1 JUCGVCVPNPBJIG-UHFFFAOYSA-N 0.000 description 2
- STVVMTBJNDTZBF-UHFFFAOYSA-N 2-amino-3-phenylpropan-1-ol Chemical compound OCC(N)CC1=CC=CC=C1 STVVMTBJNDTZBF-UHFFFAOYSA-N 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- YFMPSMITLLBENU-UHFFFAOYSA-N 3,4-dihydroxybenzylamine Chemical compound NCC1=CC=C(O)C(O)=C1 YFMPSMITLLBENU-UHFFFAOYSA-N 0.000 description 2
- QCAWOHUJKPKOMD-UHFFFAOYSA-N 4,6-diamino-1h-pyrimidine-2-thione Chemical compound NC1=CC(N)=NC(S)=N1 QCAWOHUJKPKOMD-UHFFFAOYSA-N 0.000 description 2
- LNPMZQXEPNWCMG-UHFFFAOYSA-N 4-(2-aminoethyl)aniline Chemical compound NCCC1=CC=C(N)C=C1 LNPMZQXEPNWCMG-UHFFFAOYSA-N 0.000 description 2
- VBWWCYYBZFKCEX-UHFFFAOYSA-N 6-amino-1h-1,3,5-triazine-2-thione Chemical compound NC1=NC=NC(=S)N1 VBWWCYYBZFKCEX-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- JAYBQRKXEFDRER-UHFFFAOYSA-N CC(N)C(O)C1=CC=C(O)C=C1 Chemical compound CC(N)C(O)C1=CC=C(O)C=C1 JAYBQRKXEFDRER-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- DBLDQZASZZMNSL-UHFFFAOYSA-N NC(CO)CC1=CC=C(O)C=C1 Chemical compound NC(CO)CC1=CC=C(O)C=C1 DBLDQZASZZMNSL-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- GHBAYRBVXCRIHT-VIFPVBQESA-N S-benzyl-L-cysteine zwitterion Chemical compound OC(=O)[C@@H](N)CSCC1=CC=CC=C1 GHBAYRBVXCRIHT-VIFPVBQESA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 125000001931 aliphatic group Chemical class 0.000 description 2
- 238000005937 allylation reaction Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- ANUAIBBBDSEVKN-UHFFFAOYSA-N benzene-1,2,4,5-tetramine Chemical compound NC1=CC(N)=C(N)C=C1N ANUAIBBBDSEVKN-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000002902 bimodal effect Effects 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 235000010633 broth Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 229920001600 hydrophobic polymer Polymers 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 239000011147 inorganic material Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 125000001174 sulfone group Chemical group 0.000 description 2
- 239000013076 target substance Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 2
- NFKMPKOGCRBAJF-UHFFFAOYSA-N $l^{1}-azanylformonitrile Chemical compound [N]C#N NFKMPKOGCRBAJF-UHFFFAOYSA-N 0.000 description 1
- NHUCANAMPJGMQL-ZDUSSCGKSA-N (2,5-dioxopyrrolidin-1-yl) (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoate Chemical compound C([C@H](NC(=O)OC(C)(C)C)C(=O)ON1C(CCC1=O)=O)C1=CC=CC=C1 NHUCANAMPJGMQL-ZDUSSCGKSA-N 0.000 description 1
- ZYJPUMXJBDHSIF-NSHDSACASA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-NSHDSACASA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- XEPXTKKIWBPAEG-UHFFFAOYSA-N 1,1-dichloropropan-1-ol Chemical compound CCC(O)(Cl)Cl XEPXTKKIWBPAEG-UHFFFAOYSA-N 0.000 description 1
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- XVGQHRKNXSUPEF-UHFFFAOYSA-N 2-(trifluoromethyl)benzenethiol Chemical compound FC(F)(F)C1=CC=CC=C1S XVGQHRKNXSUPEF-UHFFFAOYSA-N 0.000 description 1
- VLZVIIYRNMWPSN-UHFFFAOYSA-N 2-Amino-4-nitrophenol Chemical compound NC1=CC([N+]([O-])=O)=CC=C1O VLZVIIYRNMWPSN-UHFFFAOYSA-N 0.000 description 1
- HPILSDOMLLYBQF-UHFFFAOYSA-N 2-[1-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COC(CCC)OCC1CO1 HPILSDOMLLYBQF-UHFFFAOYSA-N 0.000 description 1
- OCYJXSUPZMNXEN-UHFFFAOYSA-N 2-amino-1-(4-nitrophenyl)propane-1,3-diol Chemical compound OCC(N)C(O)C1=CC=C([N+]([O-])=O)C=C1 OCYJXSUPZMNXEN-UHFFFAOYSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- HQWDKLAIDBOLFE-UHFFFAOYSA-M 2-fluoro-1-methylpyridin-1-ium;4-methylbenzenesulfonate Chemical class C[N+]1=CC=CC=C1F.CC1=CC=C(S([O-])(=O)=O)C=C1 HQWDKLAIDBOLFE-UHFFFAOYSA-M 0.000 description 1
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
- PXJFNILZHLDDDF-UHFFFAOYSA-N 2-sulfanyl-1h-triazine Chemical compound SN1NC=CC=N1 PXJFNILZHLDDDF-UHFFFAOYSA-N 0.000 description 1
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 1
- XYVMOLOUBJBNBF-UHFFFAOYSA-N 3h-1,3-oxazol-2-one Chemical class OC1=NC=CO1 XYVMOLOUBJBNBF-UHFFFAOYSA-N 0.000 description 1
- WPANETAWYGDRLL-UHFFFAOYSA-N 4-aminobenzenecarboximidamide Chemical compound NC(=N)C1=CC=C(N)C=C1 WPANETAWYGDRLL-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- RTNUTCOTGVKVBR-UHFFFAOYSA-N 4-chlorotriazine Chemical class ClC1=CC=NN=N1 RTNUTCOTGVKVBR-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- OZOMCUBZDWQFNI-UHFFFAOYSA-N CC(C1=CC=C(N(=O)O)C=C1)C(N)CO Chemical compound CC(C1=CC=C(N(=O)O)C=C1)C(N)CO OZOMCUBZDWQFNI-UHFFFAOYSA-N 0.000 description 1
- BEMZAFZCPNZLII-UHFFFAOYSA-N CCSCCNC(=O)C(N)C(O)C1=CC=CC=C1 Chemical compound CCSCCNC(=O)C(N)C(O)C1=CC=CC=C1 BEMZAFZCPNZLII-UHFFFAOYSA-N 0.000 description 1
- IVPZKLUALGJROZ-UHFFFAOYSA-N CCSCCNC(=O)C(N)C(O)C1=CC=CS1 Chemical compound CCSCCNC(=O)C(N)C(O)C1=CC=CS1 IVPZKLUALGJROZ-UHFFFAOYSA-N 0.000 description 1
- MZIAGSGRSKTTFH-UHFFFAOYSA-N CCSCCNC(=O)C(N)CC1=CC=CC=C1 Chemical compound CCSCCNC(=O)C(N)CC1=CC=CC=C1 MZIAGSGRSKTTFH-UHFFFAOYSA-N 0.000 description 1
- QJDBYDOJOUEPDI-UHFFFAOYSA-N CCSCCNC(=O)C(N)CSCC1=CC=CC=C1 Chemical compound CCSCCNC(=O)C(N)CSCC1=CC=CC=C1 QJDBYDOJOUEPDI-UHFFFAOYSA-N 0.000 description 1
- BKNRTJJZMZGFEH-UHFFFAOYSA-N CNC(=O)C(N)CC1=CNC=N1 Chemical compound CNC(=O)C(N)CC1=CNC=N1 BKNRTJJZMZGFEH-UHFFFAOYSA-N 0.000 description 1
- IULJJGJXIGQINK-UHFFFAOYSA-N CSC1=CC=C(C(O)C(N)CO)C=C1 Chemical compound CSC1=CC=C(C(O)C(N)CO)C=C1 IULJJGJXIGQINK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- UDQCRUSSQAXPJY-UHFFFAOYSA-N NC(CO)CC1=CNC2=C1C=CC=C2 Chemical compound NC(CO)CC1=CNC2=C1C=CC=C2 UDQCRUSSQAXPJY-UHFFFAOYSA-N 0.000 description 1
- OIDIVYIPURRQRG-UHFFFAOYSA-N NC1=C(O)C=CC(N(=O)O)=C1 Chemical compound NC1=C(O)C=CC(N(=O)O)=C1 OIDIVYIPURRQRG-UHFFFAOYSA-N 0.000 description 1
- QHGUCRYDKWKLMG-UHFFFAOYSA-N NCC(O)C1=CC=C(O)C=C1 Chemical compound NCC(O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropanol Chemical compound CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
- ATTZFSUZZUNHBP-UHFFFAOYSA-N Piperonyl sulfoxide Chemical compound CCCCCCCCS(=O)C(C)CC1=CC=C2OCOC2=C1 ATTZFSUZZUNHBP-UHFFFAOYSA-N 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 125000000909 amidinium group Chemical group 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical group OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229960004979 fampridine Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 229960000587 glutaral Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- CQRYARSYNCAZFO-UHFFFAOYSA-N o-hydroxybenzyl alcohol Natural products OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- BPUBBGLMJRNUCC-UHFFFAOYSA-N oxygen(2-);tantalum(5+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Ta+5].[Ta+5] BPUBBGLMJRNUCC-UHFFFAOYSA-N 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- BVJSUAQZOZWCKN-UHFFFAOYSA-N p-hydroxybenzyl alcohol Chemical compound OCC1=CC=C(O)C=C1 BVJSUAQZOZWCKN-UHFFFAOYSA-N 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical class OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229950009195 phenylpropanol Drugs 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Chemical group 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical group [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920002454 poly(glycidyl methacrylate) polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical class CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- HBCQSNAFLVXVAY-UHFFFAOYSA-N pyrimidine-2-thiol Chemical compound SC1=NC=CC=N1 HBCQSNAFLVXVAY-UHFFFAOYSA-N 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 238000007342 radical addition reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000010512 small scale reaction Methods 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- ATHGHQPFGPMSJY-UHFFFAOYSA-Q spermidine(3+) Chemical compound [NH3+]CCCC[NH2+]CCC[NH3+] ATHGHQPFGPMSJY-UHFFFAOYSA-Q 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003440 styrenes Chemical class 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229910001936 tantalum oxide Inorganic materials 0.000 description 1
- GSJJCZSHYJNRPN-UHFFFAOYSA-N tert-butyl n-(2-sulfanylethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCS GSJJCZSHYJNRPN-UHFFFAOYSA-N 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/20—Anion exchangers for chromatographic processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/32—Bonded phase chromatography
- B01D15/325—Reversed phase
- B01D15/327—Reversed phase with hydrophobic interaction
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/08—Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/09—Organic material
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/42—Treatment of water, waste water, or sewage by ion-exchange
Definitions
- the method comprises the steps of
- an anion-exchanger that comprises a base matrix carrying a plurality of mixed mode anion-exchange ligands comprising (a) a positively charged structure and (b) a hydrophobic structure under conditions permitting binding between the ligands and the substance, and
- the invention also relates to novel anion-exchangers in which there are anion-exchange ligands comprising both a hydrophobic structure and a positively charged structure.
- the terms “carrying a negative charge” and “negatively charged” mean that the substance carries one or more negative charges and/or has a negative net charge.
- mixed mode anion-exchanger ligand and “bimodal anion-exchanger ligand”, in the context of this invention, refer to a ligand that is capable of providing at least two different, but co-operative, sites which interact with the substance to be bound. One of these sites gives an attractive type of charge-charge interaction between the ligand and the substance of interest. The second site typically gives electron acceptor-donor interaction and/or hydrophobic interactions. Electron donor-acceptor interactions include interactions such as hydrogen-bonding, ⁇ - ⁇ , charge transfer, dipole-dipole, induced dipole etc.
- the method defined above is employed in chromatographic procedures utilizing monolithic matrices or particle matrices in form of packed or fluidised beds, and also in batch-wise procedures.
- the purpose of the procedures may be to purify a substance carrying a negative charge, in which case the substance is bound to the matrix, and, if necessary, further purified subsequent to desorption from the matrix.
- Another purpose is to remove an undesired substance that carries a negative charge from a liquid. In this latter case, the liquid may be further processed after having been contacted with the matrix in step (i). In both cases and if so desired, the matrix may be reused after desorption of the bound substance.
- the positively charged ligands typically have comprised nitrogen structures, such as primary, secondary, tertiary or quaternary ammonium structures.
- the ligands had a dual or bimodal functionality by comprising both a charged structure and a hydrophobic structure which has required modifications of the desorption protocols.
- Crowther et al J. Chrom. 282 (1983) 619-628; Crowther et al (Chromatographia 16 (1982) 349-353); Wongyai (Chromatographia 38(7/8) (1994) 485-490); Bischoff et al (J. Chrom. 270 (1983) 117-126) have described high pressure liquid chromatography of olignucleotides and small molecules on reverse phases carrying anion-exchanger ligands in which there is an aromatic component.
- Serine proteases have been affinity adsorbed/desorbed to/from matrices to which p-aminobenzamidine has been covalently linked via the para amino group. See
- WO 9729825 (Amersham Pharmacia Biotech AB) discloses mixed mode anion-exchangers providing interactions based on charges and hydrogen-bonding involving oxygen and amino nitrogen on 2-3 carbons' distance from positively charged amine nitrogen. The publication is based on the discovery that this kind of ligands can give anion-exchangers that require relatively high ionic strengths for eluting bound substances.
- WO 9965607 (Amersham Pharmacia Biotech AB) discloses cation-exchangers in which there are mixed mode ligands that require relatively high ionic strengths for eluting bound substances.
- WO 9729825 (U.S. Pat. No. 6,090,288) and WO 9965607, which give anion and cation exchange ligands, respectively, that require relatively high elution ionic strength are incorporated by reference.
- WO 9808603 (Upfront Chromatography) discloses separation media of the general structure M-SP1-L where M is a support matrix that may be hydrophilic, SP1 is a spacer and L comprises a mono- or bicyclic homoaromatic or heteroaromatic moiety that may be substituted (a homoaromatic moiety comprises an aromatic ring formed only by carbon atoms). The substituents are primarily acidic.
- the separation medium is suggested for the adsorption of proteins, in particular immunoglobulins, by hydrophobic interactions rather than ion-exchange (salt concentration up to 2 M).
- WO 9600735, WO 9609116 and U.S. Pat. No. 5,652,348 disclose separation media based on hydrophobic interaction. Adsorption and desorption are supported by increasing or decreasing, respectively, the salt concentration of the liquid or changing the charge on the ligand and/or the substance to be adsorbed/desorbed by changing pH.
- the ligands typically comprise a hydrophobic part that may comprise aromatic structure. Some of the ligands may in addition also contain a chargeable structure for permitting alteration of the hydrophobic/hydrophilic balance of the media by a pH change.
- the chargeable structure may be an amine group.
- U.S. Pat. No. 5,789,578 suggests to immobilise a thiol containing ligand, such as 3-mercaptopropionic acid, gluthathione etc, by addition of the thiol group over carbon-carbon double bond attached to a support matrix.
- the inventors in this case neither employ nor suggest the use of the material obtained for anion-exchange adsorptions.
- R is hydrogen, aryl or alkyl.
- R′ alkylene or arylene.
- X is carboxy, sulphonyl, phosphate, phosphonate, boronate, etc.
- ligands containing an aromatic ring in the proximity of the positively charged atom may provide anion-exchangers that at least partially meet these objectives.
- inclusion of other atoms or groups participating in electron-donor acceptor interactions in the proximity of the positively charged atom in anion-exchange ligands may enhance the strength of the interaction between the substance and the adsorbent.
- proximity in this context is meant that the distance between this kind of atoms or groups and the positively charged atom is 1-7 atoms, with preference for 2, 3, 4 and 5 atoms.
- Electron donor-acceptor interactions mean that an electronegative atom with a free pair of electrons acts as a donor and bind to an electron-deficient atom that acts as an acceptor for the electron pair of the donor. See Karger et al., An Introduction into Separation Science, John Wiley & Sons (1973) page 42. Illustrative examples of donor atoms/groups are:
- Typical acceptor atoms/groups are electron deficient atoms or groups, such as metal ions, cyano, nitrogen in nitro etc, and include a hydrogen bound to an electronegative atom such as HO— in hydroxy and carboxy, —NH— in amides and amines, HS— in thiol etc.
- the first aspect of the invention is thus a method for the removal of a substance that carries a negative charge and is present in an aqueous liquid (I).
- the method comprises step (i) and step (ii) as defined above.
- the main characterizing features are that
- the ligands with a spacer have the formula:
- step (ii) desorption in step (ii) is performed under anion-exchange conditions when R 1 is —C( ⁇ NH)— and the substance is a serine protease.
- R 1 is —C( ⁇ NH)— and the substance is a serine protease.
- Anion-exchange ligands as contemplated in the context of the present invention typically have molecular weights ⁇ 1000, such as ⁇ 700 daltons excluding the molecular weight contribution of halogens that may be present.
- SP is a spacer that attaches the ligand [Ar—R 1 —N + (R 2 R 3 R 4 )] to the base matrix.
- lower hydrocarbon group and lower alkyl mean C 1-10 , such as C 1-6 , saturated hydrocarbon groups that optionally are substituted and have carbon chains as discussed below for R 2-4 . See below.
- the preferred positively charged structure —N + (R 2 R 3 R 4 ) in the ligand has a pKa value that is below 12.0, such as below 10.5. This typically means that the ligand is a primary or secondary ammonium group. For measurement of pKa see under the heading “Adsorption” below.
- Ar is an aromatic ring structure
- R 1 is [(L) n R′ 1 ] m
- L is an amino nitrogen, an ether oxygen or a thioether sulphur
- R′ 1 is a bivalent linker group selected among
- R 2 , R 3 , and R 4 are selected among hydrogen and lower alkyls.
- the positive charge on the nitrogen may be more or less delocalised to atoms or groups in Ar—R 1 and/or R 2-4 .
- the aromatic ring structure Ar may comprise one or more aromatic rings, for instance a phenyl, a biphenyl or a naphthyl structure and other aromatic ring systems that comprise fused rings or bicyclic structures.
- Aromatic rings may be heterocyclic, i.e. contain one or more nitrogen, oxygen or sulphur atoms.
- the ring may have further substituents in addition to R 1 and a possible spacer. These other substituents may contain an electron donor or acceptor atom or group, for instance enabling hydrogen-bonding.
- Ar-groups are: hydoxyphenyl (2-, 3- and 4-), 2-benzimadozolyl, methylthioxyphenyl (2-, 3- and 4-), 3-indolyl, 2-hydroxy-5-nitrophenyl, aminophenyl (2-, 3- and 4-), 4-(2-aminoethyl)phenyl, 3,4-dihydroxyphenyl, 4-nitrophenyl, 3-trifluoromethylphenyl, 4-imidazolyl, 4-aminopyridine, 6-aminopyrimidyl, 2-thienyl, 2,4,5-triaminophenyl, 4-aminotriazinyl-, 4-sulphoneamidophenyl etc.
- R′ 1 is a bivalent hydrocarbon group or —C( ⁇ NH)—.
- bivalent hydrocarbon groups there are typically one or more atoms or groups participating in hydrogen-bonding or other electron acceptor-donor interactions as defined above.
- R′ 1 in form of a hydrocarbon group may be substituted with
- the carbon chain in the hydrocarbon group may be interrupted at one or more positions by thioether sulphur, ether oxygen or amine nitrogen
- the preferred hydrocarbon chains between Ar and —N + have a length of 1-20 atoms (in R′ 1 ).
- Typical R′ 1 s are selected amongst —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, —CH 2 CH(CH 3 )—, —CH 2 OCH 2 —, —C( ⁇ O)—, —C( ⁇ NH)—, —CH 2 N + (C 2 H 5 ) 2 CH 2 CH 2 —, —CH 2 CH 2 (OCH 2 CH 2 —) n′ (where n′ is an integer larger than 1, such as ⁇ 100 for instance ⁇ 25 or ⁇ 10) etc.
- R′ 1 is preferably a bivalent hydrocarbon group, such as (a) —CH 2 —, (b) —CH 2 CH 2 — possibly substituted with a hydroxy and/or a hydroxy lower alkyl or lower alkyl (for instance hydroxy methyl or methyl, respectively) at one or two of its carbon atoms, (c) —(CH 2 ) n′′ SCH 2 ) n′′′ (where n′′ and n′′′ independently are integers 1-3, such as 1 and 2, respectively), and (d) —CH 2 N + (C 2 H 5 ) 2 CH 2 CH 2 —, (e) —CH 2 CH 2 (OCH 2 CH 2 —) n′ (where n′ is 1, 2 or 3).
- a bivalent hydrocarbon group such as (a) —CH 2 —, (b) —CH 2 CH 2 — possibly substituted with a hydroxy and/or a hydroxy lower alkyl or lower alkyl (for instance hydroxy methyl or methyl
- R 2-4 are hydrogen if the spacer is attached to R′ 1 or Ar, and three if the spacer is attached to the nitrogen.
- the anion-exchanger ligands are preferably primary or secondary amine/ammonium groups
- R 2-4 alkyl groups may contain hydroge n-bonding atoms as defined above.
- a hydrogen in R 2-4 may be replaced at one or more positions with —OR′′ 1 and/or —N + (R′ 2 R′ 3 R′ 4 ), in which R′ 2-4 and R′′ 1 are hydrogen or lower alkyl.
- a carbon chain in R 2-4 may be interrupted at one or more positions with ether oxygen, thioether sulphur or amino nitrogen.
- R 2-4 may be a bivalent alkylene forming a 5- or 6-membered ring by having one end attached to the nitrogen and the other replacing a hydrogen in R 1 or one of the remaining R 2 , R 3 , and R 4 .
- R 2-4 , R′ 2-4 and R′′ 1 groups are often selected amongst lower alkyl groups having 1-3 carbon atoms.
- each sp 3 -hybridised carbon carries at most one atom selected from amino nitrogen, thioether sulphur, and ether and hydroxy oxygens.
- the spacer (SP) starts at the base matrix and extends (a) to the nitrogen in —N + (R 2 R 3 R 4 ) by replacing one of R 2-4 , or (b) to the chain of atoms connecting —N + (R 2 R 3 R 4 ) with Ar by replacing a hydrogen in R 1 , or (c) to an aromatic ring in Ar by replacing a hydrogen in Ar.
- SP always replaces a hydrogen in the ligand [Ar—R 1 —N + (R 2 R 3 R 4 )]. It is thus presumed that if the spacer binds directly to the nitrogen or the sulphur atom in the ligand, then the replaced group R 2-5 has been hydrogen.
- the spacer as such is conventional as in traditional ion exchangers and may thus comprise linear, branched, cyclic saturated, unsaturated and aromatic hydrocarbon groups (e.g. with up to 1-20, such as 1-10 carbon atoms).
- hydrocarbon groups may carry hydroxy groups, alkoxy and aryloxy and the corresponding thio analogues, and/or amino groups.
- Carbon chains may at one or more positions be interrupted by amino nitrogen, ether oxygen, thioether sulphur as discussed above for R 1-4 .
- SP may provide one or more electron donor or acceptor atoms or groups enhancing binding of the substance to the anion-exchanger as discussed above, for instance by participating in hydrogen-bonding.
- These atoms or groups may (a) be part of or attached directly to the chain of atoms in the spacer extending from the base matrix to the ligand or (b) be part of a branch group attached to this chain.
- a branch group in this context is a group which
- [0092] comprises an atom or group participating in electron-donor acceptor interaction, such as hydrogen-bonding.
- a carbon with preference for a carbonyl carbon or an sp 3 -hybridised carbon
- Typical structures in SP that are attached directly to [Ar—R 1 —N + (R 2 R 3 R 4 )] are: —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, —CH 2 CH(CH 3 )—, —C(CH 3 ) 2 —, —C(CH 2 CH 3 ) 2 —, —C(OCH 3 ) 2 —, —CH 2 OCH 2 —, —CH 2 SCH 2 —, —CH 2 NHCH 2 —, —CH 2 O—, —CH 2 CH 2 O—, —CH 2 S—, —CH 2 CH 2 S—, —CH 2 NH—, —CONH—, —NHCO—, —CONH(CH 2 ) 2 SCH 2 —, —NHCH 2 CH 2 CH 2 CH 2 CONH—, —CH 2 CH 2 NH—, —CH 2 CH(OH)CH 2 OCH 2 CH(
- the spacer may be introduced according to conventional covalent coupling methodologies including also techniques to be developed in the future.
- Illustrative coupling chemistries involve epichlorohydrin, epibromohydrin, allyl-glycidylether, bis-epoxides such as butanedioldiglycidylether, halogen-substituted aliphatic substances such as di-chloro-propanol, divinyl sulfone, carbonyldiimidazole, aldehydes such as glutaric dialdehyde, quinones, cyanogen bromide, periodates such as sodium-meta periodate, carbodiimides, chloro-triazines, sulfonyl chlorides such as tosyl chlorides and tresyl chlorides, N-hydroxy succinimides, oxazolones, maleimides, 2-fluoro-1-methylpyridinium toluene-4-sulfonates,
- the base matrix is based on organic and/or inorganic material.
- the base matrix is preferably hydrophilic and in the form of a polymer, which is insoluble and more or less swellable in water.
- Hydrophobic polymers that have been derivatized to become hydrophilic are included in this definition.
- Suitable polymers are polyhydroxy polymers, e.g. based on polysaccharides, such as agarose, dextran, cellulose, starch, pullulan, etc. and completely synthetic polymers, such as polyacrylic amide, polymethacrylic amide, poly(hydroxyalkylvinyl ethers), poly(hydroxyalkylacrylates) and polymethacrylates (e.g.
- polyglycidylmethacrylate polyvinylalcohols and polymers based on styrenes and divinylbenzenes, and copolymers in which two or more of the monomers corresponding to the above-mentioned polymers are included.
- Polymers, which are soluble in water, may be derivatized to become insoluble, e.g. by cross-linking and by coupling to an insoluble body via adsorption or covalent binding.
- Hydrophilic groups can be introduced on hydrophobic polymers (e.g. on copolymers of monovinyl and divinylbenzenes) by polymerization of monomers exhibiting groups which can be converted to OH, or by hydrophilization of the final polymer, e.g. by adsorption of suitable compounds, such as hydrophilic polymers.
- Suitable inorganic materials to be used in base matrices are silica, zirconium oxide, graphite, tantalum oxide etc.
- Preferred matrices lack groups that are unstable against hyrolysis, such as silan, ester, amide groups and groups present in silica as such. This in particular applies with respect to groups that are in direct contact with the liquids used.
- the matrix may be porous or non-porous. This means that the matrix may be fully or partially permeable (porous) or completely impermeable to the substance to be removed (non-porous), i.e. the matrix should have a Kav in the interval of 0.40-0.95 for substances to be removed. This does not exclude that Kav may be lower, for instance down to 0.10 or even lower for certain matrices, for instance having extenders. See for instance WO 9833572 (Amersham Pharmacia Biotech AB).
- the matrix is in the form of irregular or spherical particles with sizes in the range of 1-1000 ⁇ m, preferably 5-50 ⁇ m for high performance applications and 50-300 ⁇ m for preparative purposes.
- matrices have densities higher or lower than the liquid. This kind of matrices is especially applicable in large-scale operations for fluidised or expanded bed chromatography as well as for different batch wise procedures, e.g. in stirred tanks. Fluidised and expanded bed procedures are described in WO 9218237 (Amersham Pharmacia Biotech AB) and WO 9200799 (Kem-En-Tek).
- hydrophilic matrix means that the accessible surface of the matrix is hydrophilic in the sense that aqueous liquids are able to penetrate the matrix.
- accessible surfaces on a hydrophilic base matrix expose a plurality of polar groups for instance comprising oxygen and/or nitrogen atoms.
- polar groups are hydroxyl, amino, carboxy, ester, ether of lower alkyls (such as (—CH 2 CH 2 O—) n H where n is an integer).
- the level of anion-exchange ligands in the anion-exchangers used in the invention is usually selected in the interval of 0.001-4 mmol/ml matrix, such as 0.002-0.5 mmol/ml matrix, with preference for 0.005-0.3 mmol/ml matrix. Possible and preferred ranges are among others determined by the kind of matrix, ligand, substance to be removed etc. Thus, the level of anion-exchange ligands is usually within the range of 0.01-0.3 with preference for 0.01-0.1 mmol/ml for agarose based matrices.
- the interval is typically 0.01-0.6 mmol/ml matrix with subrange being 0.01-0.2 mmol/ml matrix.
- the level of the mixed mode ligand is often at the lower half part of these intervals.
- the levels of anion-exchange ligand thus are smaller than 0.150 mmol per ml matrix and/or smaller than 1 mmol per gram dry weight of matrix.
- mmol per ml matrix refers to fully sedimented matrices saturated with water.
- the capacity range refers to the capacity of the matrix in fully protonated form to bind chloride ions.
- the inventive anion-echangers/anion-exchange ligands should resist the conditions typically applied in processes comprising anion-exchange absorptions.
- essentially no reduction in total ion binding capacity is contemplated that the total ion binding capacity is reduced at most by 10%.
- anion-exchange ligand in preferred variants should only contain structures selected among pure hydrocarbon groups (including homoaromatic and heteroaromatic structures), thioether and ether groups, disulphide groups, hydroxy groups, sulphoxide or sulphone groups, carboxamide groups, sulphone amide groups, acetal and ketal groups and groups of similar hydrolytic stability.
- anion-exchanger to be used for removal of a particular substance.
- the anion-exchanger is selected among anion-exchangers that adsorb the particular substance at relatively high ionic strengths.
- the anion-exchanger (l) used should thus be capable of:
- the reference liquid typically consists of a buffered aqueous liquid and the substance.
- anion-exchangers that have an increased maximal elution ionic strength for the substance (carrying the negative charge) compared to the elution ion strength required for the same substance on a conventional anion-exchanger.
- the anion-exchanger may be selected among those requiring more than 125%, such as more than 140% or more than 200%, of the elution ionic strength required for a standard anion-exchanger at the particular conditions applied for a selected substance to be removed. See WO 9729825 (Amersham Pharmacia Biotech AB)
- the comparisons above refer to measurements performed under essentially the same conditions for anion-exchangerr (1) and (2), i.e. essentially the same support matrix (support material, bead size, pore sizes, pore volume, packing procedure etc), pH, temperature, solvent composition, number of charged ligand having the formula given above etc.
- the spacer and coupling chemistry may differ. Certain kinds of coupling chemistries may lead to cross-linking of the support matrix resulting in a more rigid matrix. In this case the flow conditions at which the comparison is made is selected at a level where the matrix is essentially non-compressed.
- anion-exchanger As a reference ion-exchanger, the commercially available anion-exchanger Q-Sepharose Fast Flow (Amersham Pharmacia Biotech, Uppsala, Sweden) was selected in the context of the present invention.
- This anion-exchanger is a strong anion-exchanger whose ligand and spacer arm structure are:
- the adsorption and/or desorption steps may be carried out as a chromatographic procedure with the anion-exchange matrix in a monolithic form or as particles in the form of a packed or a fluidised bed.
- these steps may be carried out in a batch-wise mode with the particles being more or less completely dispersed in the liquid (e.g. in a fluidised/expanded bed).
- liquids used in steps (i) and (ii) are aqueous, i.e. water, possibly mixed with a water-miscible solvent.
- a liquid sample containing the negatively charged substance is contacted with the anion-exchanger defined above under conditions permitting adsorption (binding), preferably by anion-exchange.
- binding preferably by anion-exchange.
- the substance is at least partially negative and the ligand at least partially positive.
- anion-exchanger conditions For an amphoteric substance that is present in an aqueous liquid this means a pH ⁇ pl-0.5, preferably pH ⁇ pl.
- weak anion-exchangers are buffered to a pH within the interval ⁇ pKa+2, preferably ⁇ pKa+1.
- the pKa-value of an anion-exchanger is taken as the pH at which 50% of its titratable groups are neutralized.
- the ionic strength (measured as salt concentration or conductivity) is typically below the elution ionic strength for the particular combination of ion-exchanger, substance to be bound, temperature and pH, solvent composition etc.
- One of the benefits of the invention is that by using the mixed mode anion-exchangers defined above, it will be possible to carry out adsorption/binding also at elevated ionic strengths compared to what normally has been done for conventional ion-exchangers (reference anion-exchangerrs). By matching the anion-exchanger with the substance to be removed, the adsorption may be carried out at an ionic strength that is higher than when using the reference ion-exchanger (measured at the same pH and otherwise the same conditions).
- the ionic strength may be more than 25% higher such as more than 40% higher.
- Some combinations of anion-exchanger and substance to be removed may permit adsorption at more than 100% higher ionic strength than when using the corresponding reference ion-exchanger according to above.
- adsorption according to the present invention may be performed at ionic strengths above or below 15 or 20 mS/cm.
- the ionic strength may exceed 30 mS/cm and in some cases even exceed 40 mS/cm.
- Useful ionic strengths often correspond to NaCl concentrations (pure water) ⁇ 0.1 M, such as ⁇ 0.3 M or even ⁇ 0.5 M.
- the conductivity/ionic strength to be used will depend on the ligand used, its density on the matrix, the substance to be bound, its concentration etc.
- breakthrough capacities ⁇ 200%, such as ⁇ 300% or ⁇ 500% and even ⁇ 1000% of the breakthrough capacity obtained for a particular substance with the reference anion-exchanger may be accomplished (the same conditions as discussed before).
- Desorption may be carried out according to established protocols.
- the desorption process comprises at least one of the following procedures:
- serine proteases are only desorbed under anion-exchange conditions if R′ 1 is —C( ⁇ NH)—.
- Alternative (a) when changing from aqueous liquid I to aqueous liquid II.
- Alternative (b) includes a decreased, an increased or a constant ionic strength.
- adsorption liquid aqueous liquid I
- the conditions provided by the liquid are then changed as described above until the desired substance is eluted from the matrix.
- a typical desorption process means that the ionic strength is increased compared to that used during adsorption and in many cases correspond to at least 0.4 M NaCl, such as at 0.6 M NaCl, if pH or any of the other variables except ionic strength are not changed. The actual values will depend on the various factors discussed above.
- the requirement for using an increased ionic strength for desorption may be less strict depending on the conditions provided by aqueous liquid II. See below.
- the change in conditions can be accomplished in one or more steps (step-wise gradient) or continuously (continuous gradient).
- the various variables of the liquid in contact with the matrix may be changed one by one or in combination.
- Typical salts to be used for changing the ionic strength are selected among chlorides, phosphates, sulphates etc of alkali metals or ammonium ions).
- Typical buffer components to be used for changing pH are preferably selected amongst acid-base pairs in which the buffering component can not bind to the ligand, i.e. piperazine, 1,3-diaminopropane, ethanolamine etc.
- a decrease in pH in step (ii) will reduce the negative charge of the substance to be desorbed, assist desorption and thus also reduce the ionic strength needed for release from the matrix.
- an increase in pH may result in the release of the substance or increase its binding to the ion-exchange matrix.
- Desorption may also be assisted by adjusting the polarity of liquid (II) to a value lower than the polarity of the adsorption liquid (I).
- This may be accomplished by including a water-miscible and/or less hydrophilic organic solvent in liquid II.
- solvents are acetone, methanol, ethanol, propanols, butanols, dimethyl sulfoxide, dimethyl formamide, acrylonitrile etc.
- a decrease in polarity of aqueous liquid II is likely to assist in desorption and thus also reduce the ionic strength needed for release of the substance from the matrix.
- Desorption may also be assisted by including a soluble structural analogue of the ligand [Ar—R 1 —N + (R 2 R 3 R 4 )]. Its concentration in liquid (II) should be larger than its concentration in aqueous liquid (I).
- a “structural analogue of the ligand” or “ligand analogue” is a substance that has a structural similarity with the ligand and in soluble form inhibits binding between the ligand attached to the matrix and the substance to be removed.
- the present inventive method enables high recoveries of an adsorbed substance, for instance recoveries above 60% such as above 80% or above 90%.
- Recovery is the amount of the desorbed substance compared to the amount of the substance applied to an anion-exchanger in the adsorption/binding step. In many instances, the recovery can exceed even 95% or be essentially quantitative.
- the amount of the substance applied to an anion-exchanger is in the interval of 10-80%, such as 20-60%, of the total binding capacity of the anion-exchanger for the substance.
- Removal of a substance according to the invention is primarily carried out in order to purify the substance or some other substance that is present in liquid (I).
- the present invention is primarily intended for large molecular weight substances that have several structural units that can interact with mixed mode ligands defined above.
- Appropriate substances typically have a molecular weight that is above 1000 dalton and/or are bio-organic and/or polymeric.
- the number of net negatively charged groups per molecule is typically one or more.
- the charge of the substances is dependent on pH (i.e. the substance is amphoteric).
- biomolecules those having polypeptide structure, nucleic acid structure, lipid structure, and carbohydrate structure are normally possible to remove from a liquid according to the invention (provided they have, or can be provided with, a negative charge).
- the invention is applicable also to other biomolecules and organic substances provided they meet the structural demands given above.
- the substance may be dissolved in the aqueous medium or be in the form of small bio-particles, for instance of colloidal dimensions.
- bio-particles are viruses, cells (including bacteria and other unicellular organisms) and cell aggregates and parts of cells including cell organelles.
- the invention in particular will be applicable to aqueous liquids that are derived from biological fluids comprising a substance of interest together with high concentration of salts.
- the novel anion-exchangers are likely to be extremely useful in desalting, e.g. by enabling adsorption at high ionic strength and desorption at a lowered ionic strength by first changing the pH to reduce the positive charge of the adsorbed substance.
- Typical liquids of high ionic strength that contain a target substances of interest are fermentation broths/liquids, for instance from the culturing of cells, and liquids derived therefrom.
- the cells may originate from a vertebrate, such as a mammal, or an invertebrate (for instance cultured insect cells such as cells from butterflies and/or their larvae), or a microbe (e.g. cultured fungi, bacteria, yeast etc). Included are also plant cells and other kinds of living cells, preferably cultured.
- Aqueous liquid (I) containing the substance to be removed contains particulate matter then it may be beneficial to utilize fluidised particulate support matrices carrying the novel anion-exchange ligands together with an upward flow.
- Aqueous liquids (I) of this type may originate from (a) a fermentation broth/liquid from the culture of cells, (b) a liquid containing lysed cells, (c) a liquid containing cell and/or tissue homogenates, and (d) pastes obtained from cells.
- This aspect comprises an anion-exchanger (1) comprising a plurality of anion-exchange ligands attached to a hydrophilic base matrix.
- the ligands plus spacer comply with the formula:
- the anion-exchanger (1) has a maximal breakthrough capacity somewhere in the pH-interval 2-12 for at least one of the reference proteins: ovalbumin, conalbumin, bovine serum albumin, ⁇ -lactglobulin, ⁇ -lactalbumin, lyzozyme, IgG, soybean trypsin inhibitor (STI) which is ⁇ 200%, such as ⁇ 300% or ⁇ 500% or ⁇ 1000% of the corresponding maximal breakthrough capacity obtained for a Q-exchanger (—CH 2 CH(OH)CH 2 N +( CH 3 ) 3 (anion-exchanger 2).
- the same support matrix, degree of substitution, counter-ion etc are essentially the same in the same sense as discussed above.
- the preferred reference anion-exchangerr is Q Sepharose Fast Flow as discussed above.
- the running conditions for determining breakthrough capacities of anion-exchanger (1) and anion-exchanger (2) are essentially the same as discussed elsewhere in this text.
- Breakthrough capacities are determined under the anion-exchanger conditions defined under the heading “Selection of anion-exchangerr to be used for the removal of a particular substance”.
- the relative breakthrough capacity for each reference substance is in the typical case determined separately by using an aqueous liquid consisting of a buffer and the reference substance for which breakthrough capacity is to be determined.
- At least one of SP, R′ 1 and R 2-4 typically comprises an electron acceptor-donor atom or group, as defined above for the first aspect of the invention, for instance participating in hydrogen-bonding.
- the electron donor-acceptor group or atom may for instance be present in a branch in the spacer (SP).
- This aspect is a method for testing (screening) the appropriateness of one or more anion-exchangers for removing a substance from a liquid.
- the method comprises the steps of:
- step (d) In case the degree of substitution varies between the reference anion-exchangerr and the individual anion-exchangerrs to be tested this should be accounted for when step (d) is carried out. This in particular applies if the variation in degree of substitution is large for instance with a factor greater than 3, 5 or 10 for anion-exchangerrs 1, 2 . . . n.
- test anion-exchanger/ligand in case the maximal breakthrough capacity determined for a test anion-exchanger/ligand is larger than for the reference anion-exchanger/ligand then the test anion-exchanger/ligand will have advantages over the reference anion-exchanger/ligand. This conclusion will be more pronounced in case the maximal breakthrough capacity determined for the test anion-exchanger/ligand is ⁇ 200%, such as ⁇ 300% or ⁇ 500% or ⁇ 1000% of the breakthrough capacity of the reference anion-exchanger/ligand.
- This screening method is in particular adapted for screening libraries in which at least one of the anion-exchangers 1-n are as defined
- the method also applies to cases where the anion-exchangerrs 1-n also include one or more conventional anion-exchangerrs and anion-exchangerrs in which a positively charged nitrogen is part of an aromatic ring, such as pyridine, pyrrole, imidazole etc.
- Two or more of the anion-exchangers 1-n may be tested in the method in parallel or in sequence.
- the reference anion-exchanger may have a ligand that is defined in the first and/or second aspects of the invention.
- Steps (b) and/or (c) may be performed at an ionic strength corresponding to the ionic strength of a water solution that consists of 0.1 M NaCl or more, preferably ⁇ 0.25 M NaCl. Step (b) and (c) may or may not be carried out under anion-exchanger conditions.
- tabulated or predetermined breakthrough capacities for the reference anion-exchanger may be used.
- the method also encompasses measurements carried out at different times and/or by different individuals or by machines, including using tabulated values from outside sources for the reference anion-exchanger or the reference anion-exchange ligand.
- An anion-exchanger ligand found by this screening method can often be used in an inventive manner in the method of the invention for removal of a substance from a liquid as defined above.
- This method is primarily intended for removing salt (desalting) from a liquid (I) containing a negatively charged substance as defined above, preferably amphoteric.
- desalting of a liquid will encompass any kind of ionic strength reduction by removing charged substances from the liquid.
- the ionic strength of liquid (I) is above the ionic strength of an aqueous solution of 0.1 M NaCl or 0.15 M NaCl or 0.2 M NaCl or 0.5 M NaCl.
- the method comprises the steps of:
- step (ii) B. adjusting the pH of liquid (II) in step (ii) by the use of a buffering acid-base pair to a pH value that means a lower net positive charge or zero charge or a net negative charge (if possible) on the anion-exchanger and/or a lower net negative, zero or net positive charge on the substance thereby, if necessary by combining with a lowered ionic strength and/or a lowered polarity compared to liquid (I) and/or by including a neutral structural analogue.
- a buffering acid-base pair to a pH value that means a lower net positive charge or zero charge or a net negative charge (if possible) on the anion-exchanger and/or a lower net negative, zero or net positive charge on the substance thereby, if necessary by combining with a lowered ionic strength and/or a lowered polarity compared to liquid (I) and/or by including a neutral structural analogue.
- the anion-exchanging ligand may be a primary, a secondary, a tertiary, a quaternary ammonium group, or an amidinium group.
- Heteroaromatic groups in which there is a nitrogen atom in the aromatic ring are included in the term tertiary ammonium groups.
- N-alkylated forms of such heteroaromatic groups are included in quaternary ammonium groups.
- the pKa of the ligands are found in the interval from 4 and upwards.
- the anion-exchangerrs and the ligands to be used may be of the mixed mode kind as described
- U.S. Pat. No. 6,090,288 corresponds to WO-A-9729825 (Amersham Pharmacia Biotech) and is together with the patent application under item (b) hereby incorporated by reference.
- U.S. Pat. No. 6,090,288 discloses mixed mode anion-exchangers having enhanced binding to substances based on charge interaction and hydrogen-bonding involving oxygen and amino nitrogen on 2-3 carbons' distance from positively charged amine nitrogen.
- the anion-exchangerrs under item (b) have ligands in which there is a thioether function in the proxiimity of a positively charged atom as also defined for the instant invention.
- Step (ii) as defined above means that the elution (step (ii)) will require a significantly lowered ionic strength compared to the ionic strength of liquid (I) in step (i).
- the substance can thus be eluted in concentrated form in a solution of low concentration of salt, e.g ⁇ 100 mM or even ⁇ 10 mM.
- the appropriate pH in step (ii) shall be below pl+2 or below pl+1, with preference for pH ⁇ pl, of the desired substance to be desorbed.
- pH may be adjusted between steps (i) and (ii) by the use of a buffering acid-base pair in which the acid and/or the base is volatile and/or uncharged. This will mean that the buffer components can be removed simply by evaporation after step (ii). Volatile buffer components typically have a vapour pressure that is ⁇ 1 mm Hg, such as ⁇ 10 mm Hg, at 25° C. General rules regarding selection of buffer components are given above.
- Elution by changing the pH may be supported by including an organic water-miscible solvent in liquid (II), preferably a volatile solvent with a vapour pressure ⁇ 10 mm Hg, such as ⁇ 10 mm Hg, at 25° C.
- Structural analogues should be neutral and preferably volatile as defined for a solvent.
- salt in this context is meant a compound that, when dissolved in either liquid (I) or liquid (II), forms positively charged moieties and negatively charged moieties.
- Each negatively charged moiety carries a low number of negative charges per molecule, for instance one, two or three, and is preferably non-polymeric.
- the positively charged moiety doesn't have any such restrictions. If the principle of this aspect is applied to desalting with cation exchangers the demands on the cation in the salt will correspond to those for the anion when anion-exchangerrs are used.
- This aspect of the invention also embraces the analogous aspect in which a cation exchanger is used.
- the cation exchanger may be as defined in SE 0002688-0 filed Jul. 17, 2000 (Adsorption method and ligands), WO 996507 (Amersham Pharmacia Biotech AB) etc.
- volumes of matrix refer to sedimented bed volume. Weights of matrix given in gram refer to the suction dried weight. It is understood that these matrices are still water solvated material.
- stirring refers to the use of a suspended, motor-driven stirrer since the use of a magnet bar stirrer will to damage the beads.
- Small-scale reactions (up to 20 ml) were performed in closed vials on a shaking-table. Determination of the functionality and the extent of allylation, epoxidation, or the degree of substitution of ion exchanger groups on the beads were made using conventional methods. Elementary analyses of the gels were also performed especially for analysing of the sulphur content.
- a typical example for preparing the anion-exchangerrs described above is exemplified below using Sepharose 6 Fast Flow (Amersham Pharmacia Biotech, Uppsala, Sweden) as the base matrix.
- the amines groups were introduced on the matrix directly via the nitrogen atom of the amine groups or via the sulphur atom in thiol containing derivatives.
- Derivatives containing other reactive nucleophilic groups such as phenol for example can as well be used. Coupling to the matrix was realised in preference via bromination of the allyl group and nucleophilic substitution under basic conditions. In some cases and for thiol-containing derivatives radical addition to the allyl was as well performed.
- the amine group can be introduced as a protected form and a deprotection step is then necessary.
- Amine groups can also be introduced by other conventional methods, for example reductive amination.
- Bromine was added to a stirred suspension of 100 ml of allyl activated Sepharose 6 Fast Flow (0.4 mmol allyl groups/ml drained gel), followed by 4 g of AcONa and 100 ml of distilled water, until a persistent yellow colour was obtained. Sodium formiate was then added till the suspension was fully decolourised. The reaction mixture was filtered and the gel washed with 500 ml of distilled water. A suitable aliquot of the activated gel was then transferred to a reaction vessel and coupled with the appropriate ligand according to the following procedures.
- a 30 g quantity of bromine activated gel (0.4 mmol allyl groups/ml drained gel) was transferred to a reaction vessel containing a solution of 2-(Boc-amino) ethanethiol-l (7.35 g) in water/DMSO (1:3, 40 ml). The pH was adjusted to pH 11 with 1 M NaOH. The reaction was stirred for 16 hours at 50° C. After filtration of the reaction mixture the gel was successively washed with 3 ⁇ 50 ml of distilled water, 3 ⁇ 50 ml DMSO, 3 ⁇ 50 ml of distilled water and finally with 3 ⁇ 50 ml of EtOH.
- BSA bovine serum albumin
- the Qb10%-value was evaluated at relatively high concentration of salt (0.25 M NaCl) relative to the reference anion-exchanger Q Sepharose Fast Flow that was operated under identical conditions.
- the Qb10%-values for the different anion-exchangers were determined using the method of frontal analysis described below.
- the breakthrough capacity (Q b ) was evaluated at 10% of the maximum UV detector signal (280 nm).
- the maximum UV signal was estimated by pumping the test solution directly into the UV detector.
- the breakthrough capacity was calculated from the retention volume at 10% height of the maximum signal after correction of the dead volume.
- a column equilibrated with the piperazine buffer was continuously fed (via a 150 ml superloop) with the sample solution at a flow rate of 1 ml/min (i.e. ca. 300 cm/h).
- the application of sample was continued until the A 280 of the effluent reached a level of 10% of A 280 of the sample solution.
- the breakthrough capacity of the gel Qb 10% can be calculated.
- the results obtained have formed the basis for screening a large number of “high salt ligand” candidates and the results will be presented below.
- T R10% retention time at 10% of absorbance maximum (min)
- T RD Dead time in the system (min)
- V C Column volume (mL)
- the new anion-exchange ligands have also a much higher breakthrough capacity for BSA (QbBSA) compared to Q Sepharose Fast Flow.
- QbBSA BSA
- the ligand that gave the highest Qb-value corresponds to an increase of 4300% relative the reference anion-exchanger.
- Table 1 the one that gave the lowest Qb-value corresponds to a 500% increase compared to Q Sepharose Fast Flow.
- Tyrosine 0.30 31 45 68 121 8. 2-Amino-3- 0.17 31 ne ne ne phenyl propanol 9. a-(1-amino ethyl)-4- 0.09 29 79 88 ne hydroxy benzyl alcohol 10. 2-Amino-4- na 27 ne ne ne nitrophenol 11. 2-(4-amino-phenyl) 0.20 26 99 ne ne ethyl amine 12. Noradrenaline 0.08 25 ne ne ne 13. Benzylcysteine/ na 25 ne ne cysteamine 14.
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Treatment Of Water By Ion Exchange (AREA)
- Manufacture Of Macromolecular Shaped Articles (AREA)
- Water Treatment By Sorption (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
- The present invention relates a method for the removal of a compound (=substance) carrying a negative charge from an aqueous liquid (I). The method comprises the steps of
- i) contacting the liquid with an anion-exchanger that comprises a base matrix carrying a plurality of mixed mode anion-exchange ligands comprising (a) a positively charged structure and (b) a hydrophobic structure under conditions permitting binding between the ligands and the substance, and
- ii) desorbing said substance from said matrix by the use of a liquid (II).
- The invention also relates to novel anion-exchangers in which there are anion-exchange ligands comprising both a hydrophobic structure and a positively charged structure.
- The terms “carrying a negative charge” and “negatively charged” mean that the substance carries one or more negative charges and/or has a negative net charge.
- The terms “mixed mode anion-exchanger ligand” and “bimodal anion-exchanger ligand”, in the context of this invention, refer to a ligand that is capable of providing at least two different, but co-operative, sites which interact with the substance to be bound. One of these sites gives an attractive type of charge-charge interaction between the ligand and the substance of interest. The second site typically gives electron acceptor-donor interaction and/or hydrophobic interactions. Electron donor-acceptor interactions include interactions such as hydrogen-bonding, π-π, charge transfer, dipole-dipole, induced dipole etc.
- The method defined above is employed in chromatographic procedures utilizing monolithic matrices or particle matrices in form of packed or fluidised beds, and also in batch-wise procedures. The purpose of the procedures may be to purify a substance carrying a negative charge, in which case the substance is bound to the matrix, and, if necessary, further purified subsequent to desorption from the matrix. Another purpose is to remove an undesired substance that carries a negative charge from a liquid. In this latter case, the liquid may be further processed after having been contacted with the matrix in step (i). In both cases and if so desired, the matrix may be reused after desorption of the bound substance.
- Other uses are assay procedures involving determination of either the substance carrying the negative charge or of a substance remaining in liquid I.
- In previous anion-exchange adsorptions, the positively charged ligands typically have comprised nitrogen structures, such as primary, secondary, tertiary or quaternary ammonium structures. In some instances the ligands had a dual or bimodal functionality by comprising both a charged structure and a hydrophobic structure which has required modifications of the desorption protocols.
- Simmonds et al (Biochem. J. 157 (1976) 153-159); Burton et al (J. Chromatog. A 814 (1998) 71-81); and Yon et al (Biochem. J. 151 (1975) 281-290) have described anion-exchanger ligands that comprise saturated hydrocarbon groups.
- Crowther et al (J. Chrom. 282 (1983) 619-628); Crowther et al (Chromatographia 16 (1982) 349-353); Wongyai (Chromatographia 38(7/8) (1994) 485-490); Bischoff et al (J. Chrom. 270 (1983) 117-126) have described high pressure liquid chromatography of olignucleotides and small molecules on reverse phases carrying anion-exchanger ligands in which there is an aromatic component.
- See also Sasaki et al (J. Biochem. 86 (1979) 1537-1548) in which a similar effect from an anion-exchanger based on a hydrophobic matrix is discussed.
- Serine proteases have been affinity adsorbed/desorbed to/from matrices to which p-aminobenzamidine has been covalently linked via the para amino group. See
- Chang et al (J. Chem. Tech. Biotechnol. 59 (1994) 133-139) who used an adsorption buffer in which the pH is higher and the salt concentration is lower than in the desorption buffer;
- Lee et al (J. Chromatog. A 704 (1995) 307-314) who changed the pHs in the same manner as Chang et al but without change in salt concentration; and
- Khamlichi et al., J. Chromatog. 510 (1990) 123-132 who used ligand analogues for desorption. The pH-values during adsorption and desorption were the same. Desorption by only increasing the ionic strength failed.
- None of the methodologies in these three articles describe successful desorption processes under anion-exchange conditions.
- WO 9729825 (Amersham Pharmacia Biotech AB) discloses mixed mode anion-exchangers providing interactions based on charges and hydrogen-bonding involving oxygen and amino nitrogen on 2-3 carbons' distance from positively charged amine nitrogen. The publication is based on the discovery that this kind of ligands can give anion-exchangers that require relatively high ionic strengths for eluting bound substances.
- WO 9965607 (Amersham Pharmacia Biotech AB) discloses cation-exchangers in which there are mixed mode ligands that require relatively high ionic strengths for eluting bound substances.
- WO 9729825 (U.S. Pat. No. 6,090,288) and WO 9965607, which give anion and cation exchange ligands, respectively, that require relatively high elution ionic strength are incorporated by reference.
- WO 9808603 (Upfront Chromatography) discloses separation media of the general structure M-SP1-L where M is a support matrix that may be hydrophilic, SP1 is a spacer and L comprises a mono- or bicyclic homoaromatic or heteroaromatic moiety that may be substituted (a homoaromatic moiety comprises an aromatic ring formed only by carbon atoms). The substituents are primarily acidic. The separation medium is suggested for the adsorption of proteins, in particular immunoglobulins, by hydrophobic interactions rather than ion-exchange (salt concentration up to 2 M).
- WO 9600735, WO 9609116 and U.S. Pat. No. 5,652,348 (Burton et al) disclose separation media based on hydrophobic interaction. Adsorption and desorption are supported by increasing or decreasing, respectively, the salt concentration of the liquid or changing the charge on the ligand and/or the substance to be adsorbed/desorbed by changing pH. The ligands typically comprise a hydrophobic part that may comprise aromatic structure. Some of the ligands may in addition also contain a chargeable structure for permitting alteration of the hydrophobic/hydrophilic balance of the media by a pH change. The chargeable structure may be an amine group.
- U.S. Pat. No. 5,789,578 (Burton et al) suggests to immobilise a thiol containing ligand, such as 3-mercaptopropionic acid, gluthathione etc, by addition of the thiol group over carbon-carbon double bond attached to a support matrix. The inventors in this case neither employ nor suggest the use of the material obtained for anion-exchange adsorptions.
- Dipolar adsorbents prepared by coupling sulphanilic acid using epichlorohydrin has been described (ligand+spacer=—CH2CHOHCH2N+H2C6H4SO3 −) (Porat et al., J. Chromatog. 51 (1970) 479-489; and Ohkubo et al., J. Chromatog. A, 779 (1997), 113-122). The articles do not disclose a separation method in which the ligand is positively, and the substance to be removed negatively, charged.
- WPI Abstract Accession No. 86-312313 (=DD-A-237844, Behrend et al) describes the use of 2,4,6-trihalo-1,3,5-triazine for binding substances RHNR′X to carriers inter alia to cellulose. R is hydrogen, aryl or alkyl. R′ alkylene or arylene. X is carboxy, sulphonyl, phosphate, phosphonate, boronate, etc.
- The objectives of the present invention are:
- a) to achieve adsorption/binding of negatively charged substances, such as proteins, to anion-exchangers at relatively high ionic strengths;
- b) to provide anion-exchange media that can have a reduced ligand content while retaining a sufficient capacity to bind target substances;
- c) to enable elution/desorption within broad ionic strength intervals of substances adsorbed/bound to an anion-exchangerr;
- d) to design anion-exchangers which have high breakthrough capacities, good recovery of proteins (often 95% or higher) etc;
- e) to design anion-exchangers that can resist regeneration and/or cleaning with alkaline and or acidic milieu without significant loss of chromatographic properties;
- f) to obviate extensive dilutions of samples of high ionic strength that are to be used in processes requiring a lowered ionic strength;
- g) to provide simplified desalting procedures;
- h) to provide a method for selecting anion-exchangers or anion-exchange ligands that, when bound to a support matrix, are equal or better than a conventional reference anion-exchanger in adsorbing a negatively charged substance;
- i) to provide simplified processes involving anion-exchangers, for instance to improve productivity and/or reduce the costs for process equipment and investments;
- j) to provide anion-exchangerrs that are adapted to preparative applications, for instance in large scale processes in which a sample volume (=liquid (I)) larger than a litre are applied and processed on an anion-exchangerr;
- k) to provide opportunities for novel combinations of separation principles based elution of anion-exchanger adsorbents at high salt concentration, for instance hydrophobic interaction adsorption after an ion exchange step.
- These objectives are based on the recognition that ion exchangers adsorbing at high salt concentrations and high ionic strengths have benefits. This is contrary to traditional ion exchangers which have utilized high salt concentrations and high ionic strengths in the desorption step.
- The Invention
- The present inventors have discovered that ligands containing an aromatic ring in the proximity of the positively charged atom may provide anion-exchangers that at least partially meet these objectives. The present inventors have also discovered that inclusion of other atoms or groups participating in electron-donor acceptor interactions in the proximity of the positively charged atom in anion-exchange ligands may enhance the strength of the interaction between the substance and the adsorbent.
- By proximity in this context is meant that the distance between this kind of atoms or groups and the positively charged atom is 1-7 atoms, with preference for 2, 3, 4 and 5 atoms.
- Electron donor-acceptor interactions mean that an electronegative atom with a free pair of electrons acts as a donor and bind to an electron-deficient atom that acts as an acceptor for the electron pair of the donor. See Karger et al., An Introduction into Separation Science, John Wiley & Sons (1973) page 42. Illustrative examples of donor atoms/groups are:
- (a) oxygen with a free pair of electrons, such as in hydroxy, ethers, carbonyls, and esters (—O— and —CO—O—) and amides,
- (b) sulphur with a free electron pair, such as in thioethers (—S—),
- (c) nitrogen with a free pair of electron, such as in amines, amides including sulphone amides], cyano,
- (d) halo (fluorine, chlorine, bromine and iodine), and
- (e) sp- and sp2-hybridised carbons.
- Typical acceptor atoms/groups are electron deficient atoms or groups, such as metal ions, cyano, nitrogen in nitro etc, and include a hydrogen bound to an electronegative atom such as HO— in hydroxy and carboxy, —NH— in amides and amines, HS— in thiol etc.
- The first aspect of the invention is thus a method for the removal of a substance that carries a negative charge and is present in an aqueous liquid (I). The method comprises step (i) and step (ii) as defined above. The main characterizing features are that
- the ligands with a spacer have the formula:
- --SP---[Ar—R1—N+(R2R3R4)]
- desorption in step (ii) is performed under anion-exchange conditions when R1 is —C(═NH)— and the substance is a serine protease. For desorption of other substances see under the heading “Desorption” below.
- Anion-exchange ligands as contemplated in the context of the present invention typically have molecular weights <1000, such as <700 daltons excluding the molecular weight contribution of halogens that may be present.
- The Anion-Exchanger
- In the formula --SP---[Ar—R1—N+(R2R3R4)]:
- [Ar—R1—N+(R2R3R4)] represents a ligand structure
- SP is a spacer that attaches the ligand [Ar—R1—N+(R2R3R4)] to the base matrix.
- --- represents that the spacer replaces a hydrogen in [Ar—R1—N+(R2R3R4)].
- -- represents a link to the base matrix.
- Henceforth the terms lower hydrocarbon group and lower alkyl (including lower alkylene) mean C1-10, such as C1-6, saturated hydrocarbon groups that optionally are substituted and have carbon chains as discussed below for R2-4. See below.
- The preferred positively charged structure —N+(R2R3R4) in the ligand has a pKa value that is below 12.0, such as below 10.5. This typically means that the ligand is a primary or secondary ammonium group. For measurement of pKa see under the heading “Adsorption” below.
- In the ligand [Ar—R1—N+(R2R3R4)]:
- a) Ar is an aromatic ring structure,
- b) R1 is [(L)nR′1]m where
- n and m are integers selected amongst 0 or 1, with preference for (a) m=0 or (b) n=0 when m=1;
- L is an amino nitrogen, an ether oxygen or a thioether sulphur;
- R′1 is a bivalent linker group selected among
- 1) linear, branched or cyclic hydrocarbon groups;
- 2) —C(═NH)—;
- c) R2, R3, and R4 are selected among hydrogen and lower alkyls.
- The positive charge on the nitrogen may be more or less delocalised to atoms or groups in Ar—R1 and/or R2-4. For R′1 equals —C(═NH)— (m=1), one, two or three of R2-4 are preferably hydrogen.
- The Group Ar
- The aromatic ring structure Ar may comprise one or more aromatic rings, for instance a phenyl, a biphenyl or a naphthyl structure and other aromatic ring systems that comprise fused rings or bicyclic structures. Aromatic rings may be heterocyclic, i.e. contain one or more nitrogen, oxygen or sulphur atoms. The ring may have further substituents in addition to R1 and a possible spacer. These other substituents may contain an electron donor or acceptor atom or group, for instance enabling hydrogen-bonding.
- Illustrative Ar-groups are: hydoxyphenyl (2-, 3- and 4-), 2-benzimadozolyl, methylthioxyphenyl (2-, 3- and 4-), 3-indolyl, 2-hydroxy-5-nitrophenyl, aminophenyl (2-, 3- and 4-), 4-(2-aminoethyl)phenyl, 3,4-dihydroxyphenyl, 4-nitrophenyl, 3-trifluoromethylphenyl, 4-imidazolyl, 4-aminopyridine, 6-aminopyrimidyl, 2-thienyl, 2,4,5-triaminophenyl, 4-aminotriazinyl-, 4-sulphoneamidophenyl etc.
- The Group R′1
- For m=1, R′1 is a bivalent hydrocarbon group or —C(═NH)—. In preferred bivalent hydrocarbon groups there are typically one or more atoms or groups participating in hydrogen-bonding or other electron acceptor-donor interactions as defined above. Thus R′1 in form of a hydrocarbon group may be substituted with
- a) one or more primary ammonium groups (—N+H3) in which one or more of the hydrogens may be replaced with lower alkyl, and/or
- b) one or more hydroxy (—OH) in which the hydrogen may be replaced with a lower alkyl, and/or
- the carbon chain in the hydrocarbon group may be interrupted at one or more positions by thioether sulphur, ether oxygen or amine nitrogen
- The preferred hydrocarbon chains between Ar and —N+(R2R3R4) have a length of 1-20 atoms (in R′1).
- Typical R′1s are selected amongst —CH2—, —CH2CH2—, —CH2CH2CH2—, —CH2CH(CH3)—, —CH2OCH2—, —C(═O)—, —C(═NH)—, —CH2N+(C2H5)2CH2CH2—, —CH2CH2(OCH2CH2—)n′ (where n′ is an integer larger than 1, such as ≦100 for instance ≦25 or ≦10) etc. For cases in which n=m=1, R′1 is preferably a bivalent hydrocarbon group, such as (a) —CH2—, (b) —CH2CH2— possibly substituted with a hydroxy and/or a hydroxy lower alkyl or lower alkyl (for instance hydroxy methyl or methyl, respectively) at one or two of its carbon atoms, (c) —(CH2)n″SCH2)n′″ (where n″ and n′″ independently are integers 1-3, such as 1 and 2, respectively), and (d) —CH2N+(C2H5)2CH2CH2—, (e) —CH2CH2(OCH2CH2—)n′ (where n′ is 1, 2 or 3).
- The Group R2-4
- In a preferred case two or three of R2-4 are hydrogen if the spacer is attached to R′1 or Ar, and three if the spacer is attached to the nitrogen. Thus, the anion-exchanger ligands are preferably primary or secondary amine/ammonium groups
- R2-4 alkyl groups may contain hydroge n-bonding atoms as defined above. Thus, a hydrogen in R2-4 may be replaced at one or more positions with —OR″1 and/or —N+(R′2R′3R′4), in which R′2-4 and R″1 are hydrogen or lower alkyl. In addition, a carbon chain in R2-4 may be interrupted at one or more positions with ether oxygen, thioether sulphur or amino nitrogen.
- One or more of R2-4 may be a bivalent alkylene forming a 5- or 6-membered ring by having one end attached to the nitrogen and the other replacing a hydrogen in R1 or one of the remaining R2, R3, and R4.
- If not hydrogen, one or more of R2-4, R′2-4 and R″1 groups are often selected amongst lower alkyl groups having 1-3 carbon atoms.
- In variants of R2-4, R′1-4 and R″1, each sp3-hybridised carbon carries at most one atom selected from amino nitrogen, thioether sulphur, and ether and hydroxy oxygens.
- The Spacer (SP)
- The spacer (SP) starts at the base matrix and extends (a) to the nitrogen in —N+(R2R3R4) by replacing one of R2-4, or (b) to the chain of atoms connecting —N+(R2R3R4) with Ar by replacing a hydrogen in R1, or (c) to an aromatic ring in Ar by replacing a hydrogen in Ar. SP always replaces a hydrogen in the ligand [Ar—R1—N+(R2R3R4)]. It is thus presumed that if the spacer binds directly to the nitrogen or the sulphur atom in the ligand, then the replaced group R2-5 has been hydrogen.
- The spacer as such is conventional as in traditional ion exchangers and may thus comprise linear, branched, cyclic saturated, unsaturated and aromatic hydrocarbon groups (e.g. with up to 1-20, such as 1-10 carbon atoms). As discussed above for R1-5, hydrocarbon groups may carry hydroxy groups, alkoxy and aryloxy and the corresponding thio analogues, and/or amino groups. Carbon chains may at one or more positions be interrupted by amino nitrogen, ether oxygen, thioether sulphur as discussed above for R1-4. There may also be carbonyl groups, such as in amides and ketones, and other groups having the comparable stability against hydrolysis. At most one atom selected from oxygen, sulphur and nitrogen is preferably bound to one and the same sp3-hybridised carbon atom.
- SP may provide one or more electron donor or acceptor atoms or groups enhancing binding of the substance to the anion-exchanger as discussed above, for instance by participating in hydrogen-bonding. These atoms or groups may (a) be part of or attached directly to the chain of atoms in the spacer extending from the base matrix to the ligand or (b) be part of a branch group attached to this chain. A branch group in this context is a group which
- is attached directly to the chain of atoms referred to in the preceding paragraph, and
- comprises an atom or group participating in electron-donor acceptor interaction, such as hydrogen-bonding.
- In a preferred variant, the part of SP binding directly to Ar—R1—N+(R2R3R4) is:
- a carbon with preference for a carbonyl carbon or an sp3-hybridised carbon; or
- a nitrogen with preference for an amino or amido nitrogen; or
- a sulphur with preference for a thioether sulphur; or
- an oxygen, with preference for an ether oxygen;
- with the proviso that SP is attached to a carbon in [Ar—R1—N+(R2R3R4)] for (b)-(d).
- Typical structures in SP that are attached directly to [Ar—R1—N+(R2R3R4)] are: —CH2—, —CH2CH2—, —CH2CH2CH2—, —CH2CH(CH3)—, —C(CH3)2—, —C(CH2CH3)2—, —C(OCH3)2—, —CH2OCH2—, —CH2SCH2—, —CH2NHCH2—, —CH2O—, —CH2CH2O—, —CH2S—, —CH2CH2S—, —CH2NH—, —CONH—, —NHCO—, —CONH(CH2)2SCH2—, —NHCH2CH2CH2CH2CH2CONH—, —CH2CH2NH—, —CH2CH(OH)CH2OCH2CH(OH)CH2O—, (the right valence binds to Ar—R1—N+(R2R3R4)). The remaining part of the spacer may be of the same kind as in traditional ion-exchangers.
- The spacer may be introduced according to conventional covalent coupling methodologies including also techniques to be developed in the future. Illustrative coupling chemistries involve epichlorohydrin, epibromohydrin, allyl-glycidylether, bis-epoxides such as butanedioldiglycidylether, halogen-substituted aliphatic substances such as di-chloro-propanol, divinyl sulfone, carbonyldiimidazole, aldehydes such as glutaric dialdehyde, quinones, cyanogen bromide, periodates such as sodium-meta periodate, carbodiimides, chloro-triazines, sulfonyl chlorides such as tosyl chlorides and tresyl chlorides, N-hydroxy succinimides, oxazolones, maleimides, 2-fluoro-1-methylpyridinium toluene-4-sulfonates, pyridyl disulfides and hydrazides.
- The Base Matrix
- The base matrix is based on organic and/or inorganic material.
- The base matrix is preferably hydrophilic and in the form of a polymer, which is insoluble and more or less swellable in water. Hydrophobic polymers that have been derivatized to become hydrophilic are included in this definition. Suitable polymers are polyhydroxy polymers, e.g. based on polysaccharides, such as agarose, dextran, cellulose, starch, pullulan, etc. and completely synthetic polymers, such as polyacrylic amide, polymethacrylic amide, poly(hydroxyalkylvinyl ethers), poly(hydroxyalkylacrylates) and polymethacrylates (e.g. polyglycidylmethacrylate), polyvinylalcohols and polymers based on styrenes and divinylbenzenes, and copolymers in which two or more of the monomers corresponding to the above-mentioned polymers are included. Polymers, which are soluble in water, may be derivatized to become insoluble, e.g. by cross-linking and by coupling to an insoluble body via adsorption or covalent binding. Hydrophilic groups can be introduced on hydrophobic polymers (e.g. on copolymers of monovinyl and divinylbenzenes) by polymerization of monomers exhibiting groups which can be converted to OH, or by hydrophilization of the final polymer, e.g. by adsorption of suitable compounds, such as hydrophilic polymers.
- Suitable inorganic materials to be used in base matrices are silica, zirconium oxide, graphite, tantalum oxide etc.
- Preferred matrices lack groups that are unstable against hyrolysis, such as silan, ester, amide groups and groups present in silica as such. This in particular applies with respect to groups that are in direct contact with the liquids used.
- The matrix may be porous or non-porous. This means that the matrix may be fully or partially permeable (porous) or completely impermeable to the substance to be removed (non-porous), i.e. the matrix should have a Kav in the interval of 0.40-0.95 for substances to be removed. This does not exclude that Kav may be lower, for instance down to 0.10 or even lower for certain matrices, for instance having extenders. See for instance WO 9833572 (Amersham Pharmacia Biotech AB).
- In a particularly interesting embodiment of the present invention, the matrix is in the form of irregular or spherical particles with sizes in the range of 1-1000 μm, preferably 5-50 μm for high performance applications and 50-300 μm for preparative purposes.
- An interesting form of matrices has densities higher or lower than the liquid. This kind of matrices is especially applicable in large-scale operations for fluidised or expanded bed chromatography as well as for different batch wise procedures, e.g. in stirred tanks. Fluidised and expanded bed procedures are described in WO 9218237 (Amersham Pharmacia Biotech AB) and WO 9200799 (Kem-En-Tek).
- The term hydrophilic matrix means that the accessible surface of the matrix is hydrophilic in the sense that aqueous liquids are able to penetrate the matrix. Typically the accessible surfaces on a hydrophilic base matrix expose a plurality of polar groups for instance comprising oxygen and/or nitrogen atoms. Examples of such polar groups are hydroxyl, amino, carboxy, ester, ether of lower alkyls (such as (—CH2CH2O—)nH where n is an integer).
- The level of anion-exchange ligands in the anion-exchangers used in the invention is usually selected in the interval of 0.001-4 mmol/ml matrix, such as 0.002-0.5 mmol/ml matrix, with preference for 0.005-0.3 mmol/ml matrix. Possible and preferred ranges are among others determined by the kind of matrix, ligand, substance to be removed etc. Thus, the level of anion-exchange ligands is usually within the range of 0.01-0.3 with preference for 0.01-0.1 mmol/ml for agarose based matrices. For dextran based matrices the interval is typically 0.01-0.6 mmol/ml matrix with subrange being 0.01-0.2 mmol/ml matrix. In the certain variants, for instance when R1 is —C(═NH)—, the level of the mixed mode ligand is often at the lower half part of these intervals. In these variants of the invention the levels of anion-exchange ligand thus are smaller than 0.150 mmol per ml matrix and/or smaller than 1 mmol per gram dry weight of matrix. The expression “mmol per ml matrix” refers to fully sedimented matrices saturated with water. The capacity range refers to the capacity of the matrix in fully protonated form to bind chloride ions. It includes a possible contribution also from positively charged groups other than the nitrogen in the ligand [Ar—R1—N+(R2R3R4)], for instance in the spacer or in any of the groups R2-4, R′1-4 and R″1.
- Stability of the Novel Anion-Exchangers
- The inventive anion-echangers/anion-exchange ligands should resist the conditions typically applied in processes comprising anion-exchange absorptions. As a general rule, this means that an anion-exchanger according to the invention should be able to resist 0.1 or 1 M NaOH in water for at least 10 hours with essentially no reduction in total ion binding capacity. By “essentially no reduction in total ion binding capacity” is contemplated that the total ion binding capacity is reduced at most by 10%. In structural terms this means that the anion-exchange ligand in preferred variants should only contain structures selected among pure hydrocarbon groups (including homoaromatic and heteroaromatic structures), thioether and ether groups, disulphide groups, hydroxy groups, sulphoxide or sulphone groups, carboxamide groups, sulphone amide groups, acetal and ketal groups and groups of similar hydrolytic stability.
- Selection of anion-exchanger to be used for removal of a particular substance. In the preferred variants of the inventive method the anion-exchanger is selected among anion-exchangers that adsorb the particular substance at relatively high ionic strengths. The anion-exchanger (l) used should thus be capable of:
- (a) binding the substance of interest in an aqueous reference liquid (II) at an ionic strength corresponding to 0.25 M NaCl, and
- (b) permitting a maximal break through capacity somewhere in the pH interval 2-12 for the substance ≧200%, such as ≧300% or ≧500% or ≧1000%, of the break through capacity of the substance for a conventional anion-exchanger (2) (reference anion-exchanger).
- Primarily these percentage figures apply to measurements made during anion-exchanger conditions. The reference liquid typically consists of a buffered aqueous liquid and the substance.
- An indirect way of finding this kind of anion-exchangers is to screen for anion-exchangers that have an increased maximal elution ionic strength for the substance (carrying the negative charge) compared to the elution ion strength required for the same substance on a conventional anion-exchanger. Thus, the anion-exchanger may be selected among those requiring more than 125%, such as more than 140% or more than 200%, of the elution ionic strength required for a standard anion-exchanger at the particular conditions applied for a selected substance to be removed. See WO 9729825 (Amersham Pharmacia Biotech AB)
- The comparisons above refer to measurements performed under essentially the same conditions for anion-exchangerr (1) and (2), i.e. essentially the same support matrix (support material, bead size, pore sizes, pore volume, packing procedure etc), pH, temperature, solvent composition, number of charged ligand having the formula given above etc. The breakthrough capacities are measured at the same relative concentration of the substance in the flow through (for instance c/c0=10%, for c/c0 see the experimental part). The spacer and coupling chemistry may differ. Certain kinds of coupling chemistries may lead to cross-linking of the support matrix resulting in a more rigid matrix. In this case the flow conditions at which the comparison is made is selected at a level where the matrix is essentially non-compressed.
- As a reference ion-exchanger, the commercially available anion-exchanger Q-Sepharose Fast Flow (Amersham Pharmacia Biotech, Uppsala, Sweden) was selected in the context of the present invention. This anion-exchanger is a strong anion-exchanger whose ligand and spacer arm structure are:
- —O—CH2CHOHCH2OCH2CHOHCH2N+(CH3)3.
- Its chloride ion capacity is 0.18-0.25 mmol/ml gel. The base matrix is epichlorohydrin cross-linked agarose in beaded form. The beads have diameters in the interval 45-165 μm. The exclusion limit for globular proteins is 4×106.
- Best Mode
- Based on experimental results achieved at the priority date the best ligand was considered to have n=0, m=1, R′1—N+H3=—C(═N+H2)NH2, and Ar=p-C6H4—. The formula —C(═N+H2)NH2, is only a representation of a group in which the charge in reality is delocalised over the —N—C—N— grouping and a hydrogen is binding accordingly. SP was attached to Ar via the nitrogen atom of an amido group. See further the experimental part for information about the best mode for spacer and base matrix.
- During the priority year the experimental support has been extended to a large number of various ligands. The best mode varies with substance of interest and is apparent from the experimental part in which the best ligands discovered so far are given.
- Adsorption/Desorption
- The adsorption and/or desorption steps may be carried out as a chromatographic procedure with the anion-exchange matrix in a monolithic form or as particles in the form of a packed or a fluidised bed. For particulate matrices, these steps may be carried out in a batch-wise mode with the particles being more or less completely dispersed in the liquid (e.g. in a fluidised/expanded bed).
- The liquids used in steps (i) and (ii) are aqueous, i.e. water, possibly mixed with a water-miscible solvent.
- Adsorption
- During adsorption, a liquid sample containing the negatively charged substance is contacted with the anion-exchanger defined above under conditions permitting adsorption (binding), preferably by anion-exchange. In other words the substance is at least partially negative and the ligand at least partially positive.
- By anion-exchanger is contemplated that the substance to be removed carries a negative charge and the anion-exchangerr is positively charged (=anion-exchanger conditions). For an amphoteric substance that is present in an aqueous liquid this means a pH≧pl-0.5, preferably pH≧pl.
- In the preferred variants, weak anion-exchangers (preferably present as a primary or secondary amine group in the anion-exchangerr) are buffered to a pH within the interval ≦pKa+2, preferably ≦pKa+1. The lower limit can extend down to at least pH=1 or 2 and is primarily determined by the stability of the anion-exchanger in acidic milieu and by the isoelectric point (pl) and stability of the substance to be removed. The pKa-value of an anion-exchanger is taken as the pH at which 50% of its titratable groups are neutralized.
- The ionic strength (measured as salt concentration or conductivity) is typically below the elution ionic strength for the particular combination of ion-exchanger, substance to be bound, temperature and pH, solvent composition etc. One of the benefits of the invention is that by using the mixed mode anion-exchangers defined above, it will be possible to carry out adsorption/binding also at elevated ionic strengths compared to what normally has been done for conventional ion-exchangers (reference anion-exchangerrs). By matching the anion-exchanger with the substance to be removed, the adsorption may be carried out at an ionic strength that is higher than when using the reference ion-exchanger (measured at the same pH and otherwise the same conditions). Depending on the anion-exchanger used the ionic strength may be more than 25% higher such as more than 40% higher. Some combinations of anion-exchanger and substance to be removed may permit adsorption at more than 100% higher ionic strength than when using the corresponding reference ion-exchanger according to above.
- In absolute figures the discussion in the preceding paragraph means that adsorption according to the present invention may be performed at ionic strengths above or below 15 or 20 mS/cm. The ionic strength may exceed 30 mS/cm and in some cases even exceed 40 mS/cm. Useful ionic strengths often correspond to NaCl concentrations (pure water) ≧0.1 M, such as ≧0.3 M or even ≧0.5 M. The conductivity/ionic strength to be used will depend on the ligand used, its density on the matrix, the substance to be bound, its concentration etc.
- Depending on the anion-exchanger selected, breakthrough capacities ≧200%, such as ≧300% or ≧500% and even ≧1000% of the breakthrough capacity obtained for a particular substance with the reference anion-exchanger may be accomplished (the same conditions as discussed before).
- Desorption
- Desorption may be carried out according to established protocols. Preferably the desorption process comprises at least one of the following procedures:
- (A) Increasing the salt concentration (ionic strength),
- (B) Increasing pH in order to lower the positive charge on the ligands,
- (C) Decreasing pH for decreasing a negative charge or for reversing the charge on the substance bound to the matrix,
- (D) Adding a ligand analogue or an agent (e.g. a solvent) that reduces the polarity of the aqueous liquid (I).
- According to the invention serine proteases are only desorbed under anion-exchange conditions if R′1 is —C(═NH)—.
- The conditions provided by (A)-(D) may be used in combination or alone. The proper choice will depend on the particular combination of
- (a) substance to be desorbed,
- (b) anion-exchanger (ligand, kind of matrix, spacer and ligand density), and
- (c) various variables of aqueous liquid II (composition, polarity, temperature, pH etc).
- Replacing aqueous liquid I (adsorption buffer) with aqueous liquid II (desorption buffer), thus means that at least one variable such as temperature, pH, polarity, ionic strength, content of soluble ligand analogue etc shall be changed while maintaining the other conditions unchanged so that desorption can take place.
- In the simplest cases this means:
- (a) an increase in ionic strength and/or
- (b) a decrease in pH for reducing the negative charge of the substance to be desorbed,
- when changing from aqueous liquid I to aqueous liquid II. Alternative (a) includes a decreased, a constant or an increased pH. Alternative (b) includes a decreased, an increased or a constant ionic strength.
- In chromatographic and/or batch procedures the matrix with the substance to be desorbed is present in a column or other suitable vessel in contact with the adsorption liquid (aqueous liquid I). The conditions provided by the liquid are then changed as described above until the desired substance is eluted from the matrix. After adsorption, a typical desorption process means that the ionic strength is increased compared to that used during adsorption and in many cases correspond to at least 0.4 M NaCl, such as at 0.6 M NaCl, if pH or any of the other variables except ionic strength are not changed. The actual values will depend on the various factors discussed above.
- The requirement for using an increased ionic strength for desorption may be less strict depending on the conditions provided by aqueous liquid II. See below.
- The change in conditions can be accomplished in one or more steps (step-wise gradient) or continuously (continuous gradient). The various variables of the liquid in contact with the matrix may be changed one by one or in combination.
- Typical salts to be used for changing the ionic strength are selected among chlorides, phosphates, sulphates etc of alkali metals or ammonium ions).
- Typical buffer components to be used for changing pH are preferably selected amongst acid-base pairs in which the buffering component can not bind to the ligand, i.e. piperazine, 1,3-diaminopropane, ethanolamine etc. A decrease in pH in step (ii) will reduce the negative charge of the substance to be desorbed, assist desorption and thus also reduce the ionic strength needed for release from the matrix.
- Depending on the pKa of the ligand used and the pl of the substance to be released, an increase in pH may result in the release of the substance or increase its binding to the ion-exchange matrix.
- Desorption may also be assisted by adjusting the polarity of liquid (II) to a value lower than the polarity of the adsorption liquid (I). This may be accomplished by including a water-miscible and/or less hydrophilic organic solvent in liquid II. Examples of such solvents are acetone, methanol, ethanol, propanols, butanols, dimethyl sulfoxide, dimethyl formamide, acrylonitrile etc. A decrease in polarity of aqueous liquid II (compared to aqueous liquid I) is likely to assist in desorption and thus also reduce the ionic strength needed for release of the substance from the matrix.
- Desorption may also be assisted by including a soluble structural analogue of the ligand [Ar—R1—N+(R2R3R4)]. Its concentration in liquid (II) should be larger than its concentration in aqueous liquid (I). A “structural analogue of the ligand” or “ligand analogue” is a substance that has a structural similarity with the ligand and in soluble form inhibits binding between the ligand attached to the matrix and the substance to be removed.
- Recovery
- In a sub-aspect the present inventive method enables high recoveries of an adsorbed substance, for instance recoveries above 60% such as above 80% or above 90%. Recovery is the amount of the desorbed substance compared to the amount of the substance applied to an anion-exchanger in the adsorption/binding step. In many instances, the recovery can exceed even 95% or be essentially quantitative. Typically the amount of the substance applied to an anion-exchanger is in the interval of 10-80%, such as 20-60%, of the total binding capacity of the anion-exchanger for the substance.
- The Substance to be Removed From the Liquid (I).
- Removal of a substance according to the invention is primarily carried out in order to purify the substance or some other substance that is present in liquid (I).
- The present invention is primarily intended for large molecular weight substances that have several structural units that can interact with mixed mode ligands defined above. Appropriate substances typically have a molecular weight that is above 1000 dalton and/or are bio-organic and/or polymeric. The number of net negatively charged groups per molecule is typically one or more. Preferably the charge of the substances is dependent on pH (i.e. the substance is amphoteric). Among biomolecules those having polypeptide structure, nucleic acid structure, lipid structure, and carbohydrate structure are normally possible to remove from a liquid according to the invention (provided they have, or can be provided with, a negative charge). In principle the invention is applicable also to other biomolecules and organic substances provided they meet the structural demands given above.
- The substance may be dissolved in the aqueous medium or be in the form of small bio-particles, for instance of colloidal dimensions. Illustrative examples of bio-particles are viruses, cells (including bacteria and other unicellular organisms) and cell aggregates and parts of cells including cell organelles.
- It is believed that the invention in particular will be applicable to aqueous liquids that are derived from biological fluids comprising a substance of interest together with high concentration of salts. The novel anion-exchangers are likely to be extremely useful in desalting, e.g. by enabling adsorption at high ionic strength and desorption at a lowered ionic strength by first changing the pH to reduce the positive charge of the adsorbed substance.
- Typical liquids of high ionic strength that contain a target substances of interest are fermentation broths/liquids, for instance from the culturing of cells, and liquids derived therefrom. The cells may originate from a vertebrate, such as a mammal, or an invertebrate (for instance cultured insect cells such as cells from butterflies and/or their larvae), or a microbe (e.g. cultured fungi, bacteria, yeast etc). Included are also plant cells and other kinds of living cells, preferably cultured.
- In case aqueous liquid (I) containing the substance to be removed contains particulate matter then it may be beneficial to utilize fluidised particulate support matrices carrying the novel anion-exchange ligands together with an upward flow. Aqueous liquids (I) of this type may originate from (a) a fermentation broth/liquid from the culture of cells, (b) a liquid containing lysed cells, (c) a liquid containing cell and/or tissue homogenates, and (d) pastes obtained from cells.
- The Second Aspect of the Invention
- This aspect comprises an anion-exchanger (1) comprising a plurality of anion-exchange ligands attached to a hydrophilic base matrix. The ligands plus spacer comply with the formula:
- --SP---[Ar—R1—N+(R2R3R4)]
- where the symbols have the same meaning as previously.
- The characteristic feature is that the anion-exchanger (1) has a maximal breakthrough capacity somewhere in the pH-interval 2-12 for at least one of the reference proteins: ovalbumin, conalbumin, bovine serum albumin, β-lactglobulin,α-lactalbumin, lyzozyme, IgG, soybean trypsin inhibitor (STI) which is ≧200%, such as ≧300% or ≧500% or ≧1000% of the corresponding maximal breakthrough capacity obtained for a Q-exchanger (—CH2CH(OH)CH2N+(CH3)3 (anion-exchanger 2). The same support matrix, degree of substitution, counter-ion etc are essentially the same in the same sense as discussed above. The preferred reference anion-exchangerr is Q Sepharose Fast Flow as discussed above. The running conditions for determining breakthrough capacities of anion-exchanger (1) and anion-exchanger (2) are essentially the same as discussed elsewhere in this text.
- Breakthrough capacities are determined under the anion-exchanger conditions defined under the heading “Selection of anion-exchangerr to be used for the removal of a particular substance”. The relative breakthrough capacity for each reference substance is in the typical case determined separately by using an aqueous liquid consisting of a buffer and the reference substance for which breakthrough capacity is to be determined.
- The various embodiments and their preferences are the same as above. Thus in preferred variants at least one of SP, R′1 and R2-4 typically comprises an electron acceptor-donor atom or group, as defined above for the first aspect of the invention, for instance participating in hydrogen-bonding. The electron donor-acceptor group or atom may for instance be present in a branch in the spacer (SP).
- The Third Aspect of the Invention
- This aspect is a method for testing (screening) the appropriateness of one or more anion-exchangers for removing a substance from a liquid. The method comprises the steps of:
- (a) providing a library which comprises
- (i) one or more anion-exchangers to be tested (test anion-exchangerrs, exchangers 1, 2, 3, 4 . . . n; n=an integer >0) each of which anion-exchangers differs with respect to kind of ligand (ligands 1, 2, 3, 4 . . . n), and
- (ii) a reference anion-exchanger having a reference ligand, the support matrix, counter-ion etc being essentially the same in the exchangers 1, 2, 3, 4 . . . n and in the reference anion-exchanger;
- (b) determining the maximal breakthrough capacity somewhere in the pH-interval 2-12 of exchanger 1 for the substance at a predetermined condition;
- (c) determining the maximal breakthrough capacity in the pH-interval 2-12 of the reference anion-exchanger for the substance at the same condition as in step (b);
- (d) concluding with the aid of the relation between the maximal breakthrough capacities obtained in steps (b) and (c), if anion-exchanger (1) is appropriate to use for removing the substance; and
- (e) repeating, if necessary, steps (b)-(c) for at least one of the exchangers 2, 3, 4 . . . n.
- In case the degree of substitution varies between the reference anion-exchangerr and the individual anion-exchangerrs to be tested this should be accounted for when step (d) is carried out. This in particular applies if the variation in degree of substitution is large for instance with a factor greater than 3, 5 or 10 for anion-exchangerrs 1, 2 . . . n.
- In particular it is believed that in case the maximal breakthrough capacity determined for a test anion-exchanger/ligand is larger than for the reference anion-exchanger/ligand then the test anion-exchanger/ligand will have advantages over the reference anion-exchanger/ligand. This conclusion will be more pronounced in case the maximal breakthrough capacity determined for the test anion-exchanger/ligand is ≧200%, such as ≧300% or ≧500% or ≧1000% of the breakthrough capacity of the reference anion-exchanger/ligand.
- This screening method is in particular adapted for screening libraries in which at least one of the anion-exchangers 1-n are as defined
- (a) in the first and second aspects of the present invention,
- (b) in U.S. Pat. No. 6,090,288 (Amersham Pharmacia Biotech AB), and
- (c) in International Patent Application filed in parallel with this application and based on SE 9904197-2 (A method for anion-exchange adsorption and thioether anion-exchangerrs).
- The method also applies to cases where the anion-exchangerrs 1-n also include one or more conventional anion-exchangerrs and anion-exchangerrs in which a positively charged nitrogen is part of an aromatic ring, such as pyridine, pyrrole, imidazole etc.
- Two or more of the anion-exchangers 1-n may be tested in the method in parallel or in sequence.
- The reference anion-exchanger may have a ligand that is defined in the first and/or second aspects of the invention.
- Selection of running conditions and reference anion-exchanger can be done as outlined for the first and second aspects of the invention. Steps (b) and/or (c) may be performed at an ionic strength corresponding to the ionic strength of a water solution that consists of 0.1 M NaCl or more, preferably ≧0.25 M NaCl. Step (b) and (c) may or may not be carried out under anion-exchanger conditions.
- In the third aspect of the invention, tabulated or predetermined breakthrough capacities for the reference anion-exchanger may be used. Thus the method also encompasses measurements carried out at different times and/or by different individuals or by machines, including using tabulated values from outside sources for the reference anion-exchanger or the reference anion-exchange ligand.
- An anion-exchanger ligand found by this screening method can often be used in an inventive manner in the method of the invention for removal of a substance from a liquid as defined above.
- An innovative method for lowering the salt concentration in liquids which contain proteins and the like.
- This method is primarily intended for removing salt (desalting) from a liquid (I) containing a negatively charged substance as defined above, preferably amphoteric. Henceforth the term desalting of a liquid will encompass any kind of ionic strength reduction by removing charged substances from the liquid. For the largest advantages to be accomplished the ionic strength of liquid (I) is above the ionic strength of an aqueous solution of 0.1 M NaCl or 0.15 M NaCl or 0.2 M NaCl or 0.5 M NaCl.
- The method comprises the steps of:
- (i) contacting a liquid (I) with an anion-exchanger (1) that comprises a base matrix carrying a plurality of ligands in which there is a positively charged nitrogen under conditions permitting binding between the anion-exchangerr and the substance,
- (ii) desorbing said substance from said anion-exchanger by the use of a liquid (liquid (I)).
- The method is characterized in:
- (A) selecting anion-exchanger (1) among anion-exchangers that are
- (a) capable of binding the substance of interest in an aqueous reference liquid at an ionic strength corresponding to 0.1 M NaCl, preferably 0.25 M NaCl; and
- (b) permitting a maximal breakthrough capacity in the pH interval 2-12 for the substance which is ≧100%, such as ≧125% or ≧200% or ≧300% or ≧500% or ≧1000%, of the breakthrough capacity of the substance for Q-Sepharose Fast Flow (anion-exchanger 2, Amersham Pharmacia Biotech, Uppsala, Sweden),
- said anion-exchangers (1) and (2) having essentially the same ligand density, and the breakthrough capacities being determined under the essentially same conditions.
- B. adjusting the pH of liquid (II) in step (ii) by the use of a buffering acid-base pair to a pH value that means a lower net positive charge or zero charge or a net negative charge (if possible) on the anion-exchanger and/or a lower net negative, zero or net positive charge on the substance thereby, if necessary by combining with a lowered ionic strength and/or a lowered polarity compared to liquid (I) and/or by including a neutral structural analogue.
- The anion-exchanging ligand may be a primary, a secondary, a tertiary, a quaternary ammonium group, or an amidinium group. Heteroaromatic groups in which there is a nitrogen atom in the aromatic ring are included in the term tertiary ammonium groups. In the same fashion, N-alkylated forms of such heteroaromatic groups are included in quaternary ammonium groups. The pKa of the ligands are found in the interval from 4 and upwards.
- The anion-exchangerrs and the ligands to be used may be of the mixed mode kind as described
- (a) herein or
- (b) in International Patent Application filed in parallel with this application and based on SE 9904197-2 (A method for anion-exchange adsorption and thioether anion-exchangerrs), or
- (c) in U.S. Pat. No. 6,090,288 (Amersham Pharmacia Biotech AB).
- U.S. Pat. No. 6,090,288 corresponds to WO-A-9729825 (Amersham Pharmacia Biotech) and is together with the patent application under item (b) hereby incorporated by reference. U.S. Pat. No. 6,090,288 discloses mixed mode anion-exchangers having enhanced binding to substances based on charge interaction and hydrogen-bonding involving oxygen and amino nitrogen on 2-3 carbons' distance from positively charged amine nitrogen. The anion-exchangerrs under item (b) have ligands in which there is a thioether function in the proxiimity of a positively charged atom as also defined for the instant invention.
- Step (ii) as defined above means that the elution (step (ii)) will require a significantly lowered ionic strength compared to the ionic strength of liquid (I) in step (i). The substance can thus be eluted in concentrated form in a solution of low concentration of salt, e.g ≦100 mM or even ≦10 mM. Typically the appropriate pH in step (ii) shall be below pl+2 or below pl+1, with preference for pH<pl, of the desired substance to be desorbed. Depending on the particular ligands involved, it may also be preferred to adjust pH≦pKa of the ligands/anion-exchangers used.
- pH may be adjusted between steps (i) and (ii) by the use of a buffering acid-base pair in which the acid and/or the base is volatile and/or uncharged. This will mean that the buffer components can be removed simply by evaporation after step (ii). Volatile buffer components typically have a vapour pressure that is ≧1 mm Hg, such as ≧10 mm Hg, at 25° C. General rules regarding selection of buffer components are given above.
- Elution by changing the pH may be supported by including an organic water-miscible solvent in liquid (II), preferably a volatile solvent with a vapour pressure ≧10 mm Hg, such as ≧10 mm Hg, at 25° C. Structural analogues should be neutral and preferably volatile as defined for a solvent.
- By the term salt in this context is meant a compound that, when dissolved in either liquid (I) or liquid (II), forms positively charged moieties and negatively charged moieties. Each negatively charged moiety carries a low number of negative charges per molecule, for instance one, two or three, and is preferably non-polymeric. The positively charged moiety doesn't have any such restrictions. If the principle of this aspect is applied to desalting with cation exchangers the demands on the cation in the salt will correspond to those for the anion when anion-exchangerrs are used.
- This innovative aspect is particularly useful for liquids containing the above-mentioned substances which cannot be desalted by existing methods, such as membrane filtration, dialysis, gel filtration etc, or for liquids that are handled in processes requiring low salt concentration or absence of salt, for instance affinity adsorption, mass spectrometry, etc. Thus it will be advantageous to desalting according to the invention a solution containing a desired substance before some kind of analyses is made on the substance as such.
- This aspect of the invention also embraces the analogous aspect in which a cation exchanger is used. The cation exchanger may be as defined in SE 0002688-0 filed Jul. 17, 2000 (Adsorption method and ligands), WO 996507 (Amersham Pharmacia Biotech AB) etc.
- The invention will now be illustrated with patent examples. The invention is further defined in the appending claims.
- Part I: Synthesis of Anion-Exchangerrs
- General:
- Volumes of matrix refer to sedimented bed volume. Weights of matrix given in gram refer to the suction dried weight. It is understood that these matrices are still water solvated material. For reactions on a large scale, stirring refers to the use of a suspended, motor-driven stirrer since the use of a magnet bar stirrer will to damage the beads. Small-scale reactions (up to 20 ml) were performed in closed vials on a shaking-table. Determination of the functionality and the extent of allylation, epoxidation, or the degree of substitution of ion exchanger groups on the beads were made using conventional methods. Elementary analyses of the gels were also performed especially for analysing of the sulphur content.
- A typical example for preparing the anion-exchangerrs described above is exemplified below using Sepharose 6 Fast Flow (Amersham Pharmacia Biotech, Uppsala, Sweden) as the base matrix.
- 1. Introduction of Allyl Groups on the Matrix:
- In a typical procedure allylation was carried out using allyl glycidyl ether, but note that the introduction of allyl groups on the solid support can as well be easily achieved with using allyl bromide. 80 g of Sepharose 6 Fast Flow was mixed with 0.5 g of NaBH4, 13 g of Na2SO4 and 40 ml of 50% aqueous solution of NaOH. The mixture was stirred for 1 hour at 50° C. After addition of 100 ml of allylglycidyl ether the temperature of the suspension was maintained at 50° C. and stirred for 18 hours. The mixture was filtered and the gel washed successively with 500 ml distilled water, 500 ml ethanol, 200 ml distilled water, 200 ml 0.2 M acetic acid and 500 ml distilled water.
- Titration gave a degree of substitution of 0.3 mmol of allyl/ml of settled gel. It was possible to obtain a degree of substitution of 0.45 mmol of allyl/ml gel by starting from a gel that had been drained (100 ml gel to 75 ml gel).
- 2. Introduction of Amines Groups on the Matrix:
- In a typical procedure the amines groups were introduced on the matrix directly via the nitrogen atom of the amine groups or via the sulphur atom in thiol containing derivatives. Derivatives containing other reactive nucleophilic groups such as phenol for example can as well be used. Coupling to the matrix was realised in preference via bromination of the allyl group and nucleophilic substitution under basic conditions. In some cases and for thiol-containing derivatives radical addition to the allyl was as well performed. In the case where the attachment point to the gel was achieved via other nucleophilic groups than the amine, the amine group can be introduced as a protected form and a deprotection step is then necessary.
- Amine groups can also be introduced by other conventional methods, for example reductive amination.
- 2.1. Activation of Allyl Sepharose Via Bromination:
- Bromine was added to a stirred suspension of 100 ml of allyl activated Sepharose 6 Fast Flow (0.4 mmol allyl groups/ml drained gel), followed by 4 g of AcONa and 100 ml of distilled water, until a persistent yellow colour was obtained. Sodium formiate was then added till the suspension was fully decolourised. The reaction mixture was filtered and the gel washed with 500 ml of distilled water. A suitable aliquot of the activated gel was then transferred to a reaction vessel and coupled with the appropriate ligand according to the following procedures.
- 2.1.a. Coupling of Octopamine to Sepharose 6 Fast Flow.
- 5.5 g of bromine activated gel (0.4 mmol allyl groups/ml drained gel) were transferred to a reaction vessel containing a solution of octopamine (2 g) in water (4 ml) that has been adjusted to pH 11.5 by addition of a 50% aqueous solution of NaOH. The mixture was stirred for 17 hours at 50° C. The suspension was filtered and the gel was washed successively with 3×10 ml of distilled water, 3×10 ml EtOH, 3×10 ml aqueous 0.5 M HCl and finally 3×10 ml of distilled water. The degree of substitution was 0.10 mmol amine group/ml of gel.
- 2.1.b. Coupling of 2-Amino-4-(trifluoromethyl)-benzenethiol to Sepharose 6 Fast Flow.
- 6 g of bromine activated gel (0.4 mmol allyl groups/ml drained gel) were transferred to a reaction vessel containing a solution of 2-Amino-4-(trifluoro methyl)-benzenethiol (2.5 g) in water/DMF (2:1, 4 ml) that has been adjusted to pH 11.5 by addition of a 50% aqueous solution of NaOH. The reaction was stirred for 18 hours at 60° C. The suspension was filtered and the gel was successively washed with 3×10 ml of distilled water, 3×10 ml EtOH, 3×10 ml aqueous 0.5 M HCl and finally with 3×10 ml. The degree of substitution was 0.07 mmol amine group/ml of gel.
- 2.1.c. Coupling of 2-(Boc-amino) ethanethiol to Sepharose 6 Fast Flow.
- A 30 g quantity of bromine activated gel (0.4 mmol allyl groups/ml drained gel) was transferred to a reaction vessel containing a solution of 2-(Boc-amino) ethanethiol-l (7.35 g) in water/DMSO (1:3, 40 ml). The pH was adjusted to pH 11 with 1 M NaOH. The reaction was stirred for 16 hours at 50° C. After filtration of the reaction mixture the gel was successively washed with 3×50 ml of distilled water, 3×50 ml DMSO, 3×50 ml of distilled water and finally with 3×50 ml of EtOH.
- 2.1.d. Coupling of Cysteamine to Amino Ethane Thiol Derived Sepharose 6 Fast Flow.
- The Boc protected amino ethanethiol gel (6 ml) (from 2.1.c) was treated with a 10% solution of trifluoroacetic acid in CH2Cl2 (60 ml) for 2 hours at room temperature. The suspension was filtered and the gel was washed successively with 3×10 ml CH2Cl2, 3×10 ml EtOH, and 3×10 ml of distilled water. The degree of substitution was 0.29 mmol amine group/ml of gel.
- 2.2. Direct Coupling to the Allyl Group.
- 2.2.a. Cysteamine Derived Sepharose 6 Fast Flow.
- A solution of cysteamine (4.7 g) in MeOH (15 ml) was added to a slurry of 10 ml of allyl activated Sepharose 6 Fast Flow (0.4 mmol allyl groups/ml drained gel) in MeOH (40 ml). The reaction mixture was left under UV irradiation and stirring at 40° C. for 16 hours. The reaction mixture was filtered and the gel was successively washed with 3×10 ml MeOH, 3×10 ml distilled water, 3×10 ml 0.5 M HCl and finally 3×10 ml of distilled water. The degree of substitution was 0.34 mmol amine group/ml of gel.
- 3. Coupling to Cysteamine Sepharose 6 Fast Flow:
- 3.1. Boc-L-Phenylalanine Derived Cysteamine Sepharose.
- A solution of Boc-L-Phenylalanine N-hydroxysuccinimide ester (0.44 g, 1.2 mmol) in DMF (2 ml) was added to a mixture of cysteamine Sepharose (4 ml, 0.2 mmol amine group/ml gel) and N,N-diisopropylethylamine (1 mmol) in DMF (5 ml). The reaction was allowed to continue for 18 hours at room temperature. The reaction mixture was filtered and the gel was washed successively with 3×10 ml DMF, 3×10 ml acetone, and finally 3×10 ml of distilled water. Residual amine groups were calculated to be 0.033 mmol amine group/ml of gel after titration.
- 3.2. L-Phenylalanine Derived Cysteamine Sepharose.
- The Boc protected L-phenylalanine derived cysteamine gel (3 ml) (from 3.1 or 2.1.d) was treated with a 10% solution of trifluoroacetic acid in CH2Cl2 (4 ml) for 2 hours at room temperature. The reaction mixture was filtered and the gel was washed successively with 3×10 ml CH2Cl2, 3×10 ml acetone, and 3×10 ml of distilled water. The degree of substitution of the product was 0.19 mmol amine group/ml of gel.
- 3.3. Fmoc-L-Tyrosine Derived Cysteamine Sepharose.
- A solution of Fmoc-L-tyrosine N-hydroxysuccinimide ester (1.1 mmol) in DMF (3 ml) was added to a slurry of cysteamine Sepharose (3.3 ml, 0.3 mmol amine group/ml gel) in DMF (5 ml). The mixture was stirred for 18 hours at room temperature. The suspension was filtered and the gel was washed with 3×10 ml DMF.
- 3.4. L-Tyrosine Derived Cysteamine Sepharose:
- The Fmoc protected L-tyrosine derived cysteamine gel (3.3 ml) (from 3.3) was treated with a 10% solution of 1,8-diazabicyclo[5,4,0]-undec-7-ene in DMF (10 ml) for 18 hours at room temperature. The reaction mixture was filtered and the gel was washed successively with 3×10 ml DMF, 3×10 ml acetone, and 3×10 ml of distilled water. The degree of substitution was 0,28 mmol amine group/ml of gel.
- Part II. Chromatography
- To verify that the ligands suggested in this invention adsorb proteins at higher ionic strengths than the reference anion-exchanger, breakthrough capacities of bovine serum albumin (BSA) was determined. The new “high-salt” anion-exchange ligands attached to Sepharose Fast Flow were compared to Q Sepharose Fast Flow in this study. Furthermore, the elution conductivity of three proteins, namely conalbumin (Con A), lactalbumin (Lactalb) and soybean trypsin inhibitor (STI), was also determined for all anion-exchangers. This function test was used to verify retardation at high salt conditions for other proteins as well. Four of the “high-salt” anion-exchanger ligands with high breakthrough capacities were also tested with respect of recovery of the protein (BSA) applied.
- A. Breakthrough Capacity (Qb10%) at High Salt Condition
- The Qb10%-value was evaluated at relatively high concentration of salt (0.25 M NaCl) relative to the reference anion-exchanger Q Sepharose Fast Flow that was operated under identical conditions. The Qb10%-values for the different anion-exchangers were determined using the method of frontal analysis described below.
- I. Buffer and Sample Solutions
- The sample solution was BSA dissolved in 20 mM piperazin (pH=6.0) with 0.25 M NaCl added. The concentration of BSA was 4 mg/ml. Buffer and sample solutions were filtered through 0.45 μm Millipore Millex HA filters before use.
- II. Chromatographic System
- All experiments were performed at room temperature using Akta Explorer 100 chromatography system (Amersham Pharmacia Biotech AB, Uppsala, Sweden) equipped with Unicorn 3.1 software. Samples were applied to the column via a 150 ml superloop. A flow rate of 1 ml/min (ca 300 cm/h) was used throughout. The effluents were monitored continuously by absorbance measurements at 280 nm using a 10 mm flow cell.
- III. Frontal Analysis
- Each prototype anion-exchanger was packed in a HR 5/5 column (packed bed volume=1) and equilibrated with the piperazine buffer (20 mM piperazin, pH=6.0, with 0.25 M NaCl). The breakthrough capacity (Qb) was evaluated at 10% of the maximum UV detector signal (280 nm). The maximum UV signal was estimated by pumping the test solution directly into the UV detector. The breakthrough capacity was calculated from the retention volume at 10% height of the maximum signal after correction of the dead volume.
- A column equilibrated with the piperazine buffer was continuously fed (via a 150 ml superloop) with the sample solution at a flow rate of 1 ml/min (i.e. ca. 300 cm/h). The application of sample was continued until the A280 of the effluent reached a level of 10% of A280 of the sample solution. On the basis of data so obtained (i.e. volume of the packed gel bed (Vc), its void volume, flow rate and concentration of BSA to the column), the breakthrough capacity of the gel (Qb 10%) can be calculated. The results obtained have formed the basis for screening a large number of “high salt ligand” candidates and the results will be presented below.
- IV. Evaluation
- The breakthrough capacity at a level of 10% of absorbance maximum of the BSA sample solution (QbBSA) was calculated with the formula:
- QbBSA=(T R10%−T RD)×C/Vc
- where:
- TR10%=retention time at 10% of absorbance maximum (min)
- TRD=Dead time in the system (min)
- C=Concentration of BSA (4 mg/mL)
- VC=Column volume (mL)
- B. Function Test
- The anion-exchange media were packed in 1.0 ml HR 5/5 columns and equilibrated with 20 column volumes of the A-buffer (20 mM phosphate buffer; pH 6.8). 50 μl of a protein mixture (6 mg/ml Con A, 4 mg/ml Lactalbumin and 6 mg/ml STI) were applied to the column and eluted with a linear gradient (gradient volume=20 column volumes) to 100% of the B-buffer (A-buffer plus 2.0 M NaCl). The flow rate was adjusted to 0.3 ml/min (100 cm/h). All experiments were performed at room temperature using Äkta Explorer 100 chromatography system equipped with Unicorn 3.1 software.
- C. Recovery of BSA Bound to “High Salt” Anion-Exchanger Ligands
- Details concerning type of column, packed bed volume, buffers, protein solution, flow rate and type of apparatus are outlined above. To a column equilibrated with piperazine buffer (20 mM piperazine, pH=6.0, with 0.25 M NaCl) was applied a solution of BSA from a 50 ml super loop until an amount corresponding to 30% of its breakthrough capacity was applied. The column was then washed with 2 bed volumes of the equilibrium buffer and the bound BSA was eluted with the appropiate de-sorption buffer. In case of ligands (Tyrosine) and (2-Aminobenzimidazole) adsorbed BSA were eluted with a piperazinee buffer (20 mM piperazine, pH=6.0, with 2.0 M NaCl). In addition, adsorbed BSA on ligands (Octopamine) and (Tyrosinol) were eluted with a TRIS buffer (0.2 M TRISS, pH=9.0, with 2 M NaCl).
- Results
- The results obtained for breakthrough capacities for a series of representative “high salt” anion-exchanger ligands are summarised in Table 1 and the structures of the ligands are depicted in section part III. The degree of ligand substitution on the majority of these new anion-exchangers was ca. 0.05-0.3 mmol/ml packed gel. As a reference anion-exchanger, the commercially available Q Sepharose Fast Flow was used. The ligand density is in the same range as the new series of anion-exchangers. The results indicate the following trends.
- 1. The new anion-exchange ligands have much higher elution conductivity for all three proteins compared to the reference anion-exchangerr Q Sepharose Fast Flow (Table 1).
- 2. The new anion-exchange ligands have also a much higher breakthrough capacity for BSA (QbBSA) compared to Q Sepharose Fast Flow. The ligand that gave the highest Qb-value corresponds to an increase of 4300% relative the reference anion-exchanger. Of the presented ligands (Table 1), the one that gave the lowest Qb-value corresponds to a 500% increase compared to Q Sepharose Fast Flow.
- 3. All good anion-exchange ligands are primary or secondary amines or both primary and secondary amines. No good ligand based on a quartenary amine has been found.
- 4. The recovery data from good anion-exchange ligands (7, 5, 27 and 4) show that adsorbed BSA can be eluted by a salt step (7 and 5) and/or a combined pH and salt step (2 and 4) with recoveries larger than 80% (see Part III).
TABLE 1 Elution conductivity at pH 6 for three proteins and breakthrough capacity of BSA (pH 6 and 0.25 M NaCl) on different anion-exchangers. Break- through Elution conductivity Ligand Capacity Lactalbumi density QbBSA ConA ne STI Ligand mmol/ml (mg/ml) (mS/cm) (mS/cm) (mS/cm) Q Sepharose Fast Flow 0.21 1 12 20 30 1. Thiomicamine 0.13 43 ne ne ne 2. Tyrosinol 0.13 39 132 ne ne 3. Tryptophanol 0.15 37 ne ne ne 4. Octopamine 0.10 37 ne ne ne 5. 2-Aminobenz- 0.17 34 46 117 ne imidazole 6. Phenylalanine/ 0.20 33 ne ne ne cysteamine 7. Tyrosine 0.30 31 45 68 121 8. 2-Amino-3- 0.17 31 ne ne ne phenyl propanol 9. a-(1-amino ethyl)-4- 0.09 29 79 88 ne hydroxy benzyl alcohol 10. 2-Amino-4- na 27 ne ne ne nitrophenol 11. 2-(4-amino-phenyl) 0.20 26 99 ne ne ethyl amine 12. Noradrenaline 0.08 25 ne ne ne 13. Benzylcysteine/ na 25 ne ne ne cysteamine 14. 2-Amino-1-(4- 0.09 23 ne ne ne nitrophenyl) 1,3-propanediol 15. 2-Amino-1-phenyl- 0.09 22 24 81 ne 1,3-propanediol 16. 2-Amino-4- 0.01 21 ne ne ne (trifluoromethyl)- benzenethiol 17. 3,4-Dihydroxy 0.11 18 46 65 110 benzylamine 18. p-Aminobenz- 0.10 17 43 62 ne amidine 19. Boc-His(Boc)-Osu 0.30 17 21 39 78 20. 4,6-Diamino-2- 0.10 14 ne ne ne mercapto pyrimidine 21. na 14 29 54 78 Treophenylserine/ cysteamine 22. Tyrosinol 0.07 13 ne ne ne 23. 4-Aminothio phenol 0.05 13 ne ne ne 24. Thienylserine/ na 12 27 50 72 cysteamine 25. 1,2,4,5-Tetra 0.10 9 71 ne ne aminobenzene 26. 4-Amino-1,3,5- 0.07 9 na na na triazine-2-thiol 27. Sulfanilamide 0.05 8 ne 63 ne 28. 4-Aminophenol 0.05 5 ne 40 ne - Part III. Ligands and Recovery.
-
-
-
-
-
-
-
-
-
-
-
- 11. 2-(4-aminophenyl) ethylamine:
- Ar=4-(2-aminoethyl)phenyl, m=0, SP ends with —CH2CH(OH)CH2O— (coupling at aromatic amino group).
-
-
-
-
-
-
-
-
-
- 21. Treophenylserine/cysteamine: Ar=phenyl, n=0, m=1, R′1=—CH(OH)CH<, SP attaches at R′1 and ends with —CONHCH2CH2SCH2—.
-
-
-
-
-
-
-
- 28. 4-aminophenol: Ar=4-hydroxyphenyl, m=0, SP attaches at amino and ends with —NHCH2CH(OH)CH2— (coupling at the amino group). Ligand density: low
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/723,362 US20040079702A1 (en) | 1999-11-22 | 2003-11-26 | Method for anion-exchange adsorption and anion-exchangers |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9904197-2 | 1999-11-22 | ||
SE9904197A SE9904197D0 (en) | 1999-11-22 | 1999-11-22 | An method for anion exchange adsorption on matrices carrying mixed mode ligands |
US10/130,958 US6702943B1 (en) | 1999-11-22 | 2000-11-22 | Method for anion-exchange adsorption and anion-exchangers |
US10/723,362 US20040079702A1 (en) | 1999-11-22 | 2003-11-26 | Method for anion-exchange adsorption and anion-exchangers |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/011605 Division WO2001038227A2 (en) | 1999-11-22 | 2000-11-22 | A method for anion-exchange adsorption and anion-exchangers |
US10/130,958 Division US6702943B1 (en) | 1999-11-22 | 2000-11-22 | Method for anion-exchange adsorption and anion-exchangers |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040079702A1 true US20040079702A1 (en) | 2004-04-29 |
Family
ID=20417786
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/148,032 Active 2026-03-31 US7879244B1 (en) | 1999-11-22 | 2000-11-22 | Method for anion-exchange adsorption and thioether anion-exchangers |
US10/130,958 Expired - Lifetime US6702943B1 (en) | 1999-11-22 | 2000-11-22 | Method for anion-exchange adsorption and anion-exchangers |
US10/723,362 Abandoned US20040079702A1 (en) | 1999-11-22 | 2003-11-26 | Method for anion-exchange adsorption and anion-exchangers |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/148,032 Active 2026-03-31 US7879244B1 (en) | 1999-11-22 | 2000-11-22 | Method for anion-exchange adsorption and thioether anion-exchangers |
US10/130,958 Expired - Lifetime US6702943B1 (en) | 1999-11-22 | 2000-11-22 | Method for anion-exchange adsorption and anion-exchangers |
Country Status (10)
Country | Link |
---|---|
US (3) | US7879244B1 (en) |
EP (2) | EP1235749B1 (en) |
JP (2) | JP5051957B2 (en) |
AT (2) | ATE496007T1 (en) |
AU (2) | AU782945B2 (en) |
CA (2) | CA2389515C (en) |
DE (1) | DE60045558D1 (en) |
IL (2) | IL149783A (en) |
SE (1) | SE9904197D0 (en) |
WO (2) | WO2001038227A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080169242A1 (en) * | 2005-05-24 | 2008-07-17 | Waters Investments Limited | Methods for separating and analyzing anionic compounds |
US20100084343A1 (en) * | 2007-02-16 | 2010-04-08 | Mader Brian T | System and process for the removal of fluorochemicals from water |
EP2625142A4 (en) * | 2010-10-05 | 2014-05-07 | Bio Works Technologies Ab | Method for removing arsenic from water using polymer based matrices with chelating groups comprising metal ions |
WO2024233291A3 (en) * | 2023-05-05 | 2024-12-19 | Bio-Rad Laboratories, Inc. | Multimodal chromatography resins with anionic and cationic ligands |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0002688D0 (en) * | 2000-07-17 | 2000-07-17 | Amersham Pharm Biotech Ab | Adsorption method and ligands |
ATE334746T1 (en) * | 2000-12-31 | 2006-08-15 | Ge Healthcare Bio Sciences Ab | METHOD FOR PRODUCING LOW SALT CONCENTRATION COMPOSITIONS |
SE0004932D0 (en) | 2000-12-31 | 2000-12-31 | Apbiotech Ab | A method for mixed mode adsorption and mixed mode adsorbents |
SE0103084D0 (en) * | 2001-09-14 | 2001-09-14 | Amersham Pharm Biotech Ab | Generation of ion exchange media |
SE0200543D0 (en) * | 2002-02-21 | 2002-02-21 | Amersham Biosciences Ab | Method of separation using aromatic thioether ligands |
ATE418385T1 (en) * | 2003-03-05 | 2009-01-15 | Ge Healthcare Bio Sciences Ab | METHOD FOR PRODUCING MULTIMODAL ANION EXCHANGE LIGANDS |
SE0300612D0 (en) * | 2003-03-05 | 2003-03-05 | Amersham Biosciences Ab | A method of preparing ligands for hydrophobic interaction chromatography |
SE0300624D0 (en) * | 2003-03-05 | 2003-03-05 | Amersham Biosciences Ab | A method of preparing affinity ligands |
SE0300791D0 (en) * | 2003-03-20 | 2003-03-20 | Amersham Biosciences Ab | Use of ph-responsive polymers |
US7700743B2 (en) * | 2003-07-22 | 2010-04-20 | Millipore Corporation | Immobilised affinity medium and its use in separation |
US7045059B2 (en) * | 2003-07-28 | 2006-05-16 | Sielc Technologies Corp | Universal bonded phase material for chromatographic separation |
EP1729882A1 (en) | 2004-02-05 | 2006-12-13 | Millipore Corporation | Porous adsorptive or chromatographic media |
JP4848356B2 (en) * | 2004-02-27 | 2011-12-28 | ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ | Antibody purification method |
SE0401665D0 (en) * | 2004-06-24 | 2004-06-24 | Amersham Biosciences Ab | Purification of immunoglobulins |
US9266041B2 (en) * | 2004-10-21 | 2016-02-23 | Ge Healthcare Bio-Sciences Ab | Chromatography ligand |
CA2583578C (en) | 2004-10-21 | 2014-04-01 | Ge Healthcare Bio-Sciences Ab | Chromatography ligand |
EP1693108A1 (en) * | 2004-12-04 | 2006-08-23 | MERCK PATENT GmbH | Mixed-modal anion-exchange type separation material |
WO2006078163A2 (en) * | 2005-01-18 | 2006-07-27 | Dolphys Technologies B.V. | High molecular weight non-ionic surfactants comprising nitrogen or phosphorus containing groups |
PL1841743T3 (en) | 2005-01-26 | 2016-06-30 | Allergan Inc | 3-Aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immuno stimulant activity |
TW200639190A (en) * | 2005-02-04 | 2006-11-16 | Showa Denko Kk | Packing material for ion chromatography |
ES2528426T3 (en) | 2005-08-03 | 2015-02-09 | Merck Patent Gmbh | Crosslinked Hydrophilic Polymer |
EP1754534A1 (en) | 2005-08-03 | 2007-02-21 | MERCK PATENT GmbH | Crosslinked hydrophile polymer |
WO2007064281A1 (en) * | 2005-12-02 | 2007-06-07 | Ge Healthcare Bio-Sciences Ab | Hydrophobic interaction chromatography |
CN101489655A (en) | 2006-07-14 | 2009-07-22 | 威斯康星旧生研究基金会 | Adsorptive membranes for trapping viruses |
EP2099957A1 (en) * | 2007-01-10 | 2009-09-16 | GE Healthcare Bio-Sciences AB | Multi-modal ion exchange chromotography resins |
US9314466B2 (en) | 2007-03-06 | 2016-04-19 | Allergan, Inc. | Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds |
US20140179925A1 (en) | 2009-09-04 | 2014-06-26 | Allergan, Inc. | Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds |
WO2008109285A1 (en) | 2007-03-06 | 2008-09-12 | Allergan, Inc. | Methods for treating cognitive disorders |
DK2481407T3 (en) | 2007-03-06 | 2019-01-07 | Allergan Inc | RELATIONSHIPS TO USE IN TREATMENT OF COGNITIVE DISORDERS |
EP2167229A4 (en) | 2007-07-25 | 2012-02-01 | Ge Healthcare Bio Sciences Ab | SEPARATION MATRIX |
US9433922B2 (en) | 2007-08-14 | 2016-09-06 | Emd Millipore Corporation | Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same |
CA2720615C (en) | 2008-04-08 | 2016-06-07 | Bio-Rad Laboratories, Inc. | Chromatography purification of antibodies |
WO2009145722A1 (en) * | 2008-05-30 | 2009-12-03 | Ge Healthcare Bio-Sciences Ab | Separation method utilizing polyallylamine ligands |
SG178173A1 (en) | 2009-07-28 | 2012-03-29 | Instraction Gmbh | Specific sorbent for binding proteins and peptides, and separation method using the same |
EP2822687B1 (en) | 2012-03-08 | 2019-11-27 | Bio-rad Laboratories, Inc. | Anionic exchange-hydrophobic mixed mode |
US20130337027A1 (en) * | 2012-05-24 | 2013-12-19 | Massachusetts Institute Of Technology | Medical Devices and Implements with Liquid-Impregnated Surfaces |
US9175279B1 (en) | 2013-03-15 | 2015-11-03 | Csl Limited | Method of purifying factor VII and/or factor VIIa |
JP6702587B2 (en) | 2014-03-14 | 2020-06-03 | ジーイー・ヘルスケア・バイオプロセス・アールアンドディ・アクチボラグ | Separation matrix for purification of biological particles |
US11584777B2 (en) * | 2017-08-31 | 2023-02-21 | Green Cross Corporation | Method for purifying a sulfatase protein |
MX2020008000A (en) * | 2018-01-30 | 2021-01-08 | Exothera Sa | Protein purification process. |
US11045773B2 (en) | 2018-08-31 | 2021-06-29 | Pall Corporation | Salt tolerant porous medium |
US10737259B2 (en) | 2018-08-31 | 2020-08-11 | Pall Corporation | Salt tolerant anion exchange medium |
WO2021092328A1 (en) * | 2019-11-07 | 2021-05-14 | Waters Technologies Corporation | Materials and methods for mixed mode, anion exchange reversed phase liquid chromatography |
CN113101909B (en) * | 2021-05-11 | 2023-07-18 | 博格隆(浙江)生物技术有限公司 | Chromatography medium and preparation method thereof |
CN116262222B (en) * | 2023-01-09 | 2024-07-30 | 浙江纽龙合成材料制造有限公司 | Preparation method of diethylaminoethyl natural polysaccharide chromatographic medium |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3234199A (en) * | 1958-12-18 | 1966-02-08 | Allen F Reid | Ion exchange process for separating proteins |
US4100149A (en) * | 1975-08-28 | 1978-07-11 | Rhone-Poulenc Industries | Method of separating proteins by ion exchange |
US4177038A (en) * | 1976-05-18 | 1979-12-04 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschafen E.V. | Method for the production of a vehicle substance which is capable of covalent bonding with biologically active matter |
US4229342A (en) * | 1977-05-18 | 1980-10-21 | Rhone-Poulenc Industries | Process for extracting proteins from milk using silica and anion exchange resins |
US4431528A (en) * | 1981-07-14 | 1984-02-14 | Ec Erdolchemie Gmbh | Process for the hydrogenation of hydrocarbons |
US4883598A (en) * | 1987-08-14 | 1989-11-28 | Waander Riethorst | Process for isolating coagulation factors, and adsorbent material suitable therefor |
US5238663A (en) * | 1990-09-13 | 1993-08-24 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Nickel recovery process |
US6090288A (en) * | 1996-02-19 | 2000-07-18 | Amersham Pharmacia Biotech Ab | Process for chromatographic separation of peptides and nucleic acid, and new high affinity ion exchange matrix |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5521763B2 (en) * | 1973-07-07 | 1980-06-12 | ||
JPS5412911B2 (en) * | 1973-07-23 | 1979-05-26 | ||
FR2321932A1 (en) * | 1975-08-28 | 1977-03-25 | Rhone Poulenc Ind | Separating proteins from aq. soln. contg. industrial effluent - by passing through ion exchange resin on mineral support |
NZ187301A (en) * | 1977-05-18 | 1981-03-16 | Rhone Poulenc Ind | Extracting proteins from milk by anion-exchange resin and silica |
GB2050192A (en) * | 1979-07-18 | 1981-01-07 | Northern Eng Ind | Monitoring sodium content of condensates during polishing |
DE3411420A1 (en) * | 1984-03-28 | 1985-10-10 | L. & C. Steinmüller GmbH, 5270 Gummersbach | Method for establishing the breakthrough point of a cation exchanger in an installation for desalinating water or aqueous solutions |
DD237844A1 (en) * | 1985-05-29 | 1986-07-30 | Akad Wissenschaften Ddr | METHOD FOR PRODUCING CATION-ACTIVE ION EXCHANGERS |
JPH0668081B2 (en) * | 1988-08-18 | 1994-08-31 | 富士写真フイルム株式会社 | Polymer composite with anion exchange capacity |
GB8912903D0 (en) * | 1989-06-05 | 1989-07-26 | Smith Kline French Lab | Compounds |
DE4010265C2 (en) * | 1990-03-30 | 1997-07-24 | Karlsruhe Forschzent | Process for the separate extraction of complex images and uncomplexed metal ions from waste water |
SE9004129D0 (en) * | 1990-12-21 | 1990-12-21 | Pharmacia Lkb Biotech | ANION EXCHANGER |
US20040214157A1 (en) | 1994-06-29 | 2004-10-28 | Simon C. Burton | Chromatographic resins and methods for using same |
US5652348A (en) | 1994-09-23 | 1997-07-29 | Massey University | Chromatographic resins and methods for using same |
SE9700383D0 (en) | 1997-02-04 | 1997-02-04 | Pharmacia Biotech Ab | An adsorption / separation method and a medium for adsorption / separation |
SE9802214D0 (en) * | 1998-06-18 | 1998-06-18 | Amersham Pharm Biotech Ab | Ion exchanger and its use |
-
1999
- 1999-11-22 SE SE9904197A patent/SE9904197D0/en unknown
-
2000
- 2000-11-22 IL IL14978300A patent/IL149783A/en not_active IP Right Cessation
- 2000-11-22 CA CA2389515A patent/CA2389515C/en not_active Expired - Fee Related
- 2000-11-22 EP EP00988740A patent/EP1235749B1/en not_active Expired - Lifetime
- 2000-11-22 EP EP00979615A patent/EP1235748B1/en not_active Expired - Lifetime
- 2000-11-22 DE DE60045558T patent/DE60045558D1/en not_active Expired - Lifetime
- 2000-11-22 US US10/148,032 patent/US7879244B1/en active Active
- 2000-11-22 AT AT00988740T patent/ATE496007T1/en not_active IP Right Cessation
- 2000-11-22 JP JP2001539791A patent/JP5051957B2/en not_active Expired - Lifetime
- 2000-11-22 WO PCT/EP2000/011605 patent/WO2001038227A2/en active IP Right Grant
- 2000-11-22 IL IL14978200A patent/IL149782A0/en not_active IP Right Cessation
- 2000-11-22 AU AU17044/01A patent/AU782945B2/en not_active Ceased
- 2000-11-22 WO PCT/EP2000/011606 patent/WO2001038228A1/en active IP Right Grant
- 2000-11-22 AU AU25079/01A patent/AU780286B2/en not_active Ceased
- 2000-11-22 CA CA2392200A patent/CA2392200C/en not_active Expired - Fee Related
- 2000-11-22 AT AT00979615T patent/ATE517064T1/en not_active IP Right Cessation
- 2000-11-22 US US10/130,958 patent/US6702943B1/en not_active Expired - Lifetime
- 2000-11-22 JP JP2001539792A patent/JP4814467B2/en not_active Expired - Lifetime
-
2003
- 2003-11-26 US US10/723,362 patent/US20040079702A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3234199A (en) * | 1958-12-18 | 1966-02-08 | Allen F Reid | Ion exchange process for separating proteins |
US4100149A (en) * | 1975-08-28 | 1978-07-11 | Rhone-Poulenc Industries | Method of separating proteins by ion exchange |
US4177038A (en) * | 1976-05-18 | 1979-12-04 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschafen E.V. | Method for the production of a vehicle substance which is capable of covalent bonding with biologically active matter |
US4229342A (en) * | 1977-05-18 | 1980-10-21 | Rhone-Poulenc Industries | Process for extracting proteins from milk using silica and anion exchange resins |
US4431528A (en) * | 1981-07-14 | 1984-02-14 | Ec Erdolchemie Gmbh | Process for the hydrogenation of hydrocarbons |
US4883598A (en) * | 1987-08-14 | 1989-11-28 | Waander Riethorst | Process for isolating coagulation factors, and adsorbent material suitable therefor |
US5238663A (en) * | 1990-09-13 | 1993-08-24 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Nickel recovery process |
US6090288A (en) * | 1996-02-19 | 2000-07-18 | Amersham Pharmacia Biotech Ab | Process for chromatographic separation of peptides and nucleic acid, and new high affinity ion exchange matrix |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080169242A1 (en) * | 2005-05-24 | 2008-07-17 | Waters Investments Limited | Methods for separating and analyzing anionic compounds |
US8048305B2 (en) * | 2005-05-24 | 2011-11-01 | Waters Technologies Corporation | Methods for separating and analyzing anionic compounds |
US20100084343A1 (en) * | 2007-02-16 | 2010-04-08 | Mader Brian T | System and process for the removal of fluorochemicals from water |
KR101500018B1 (en) * | 2007-02-16 | 2015-03-06 | 쓰리엠 이노베이티브 프로퍼티즈 캄파니 | System and method for removing fluorine-based materials from water |
EP2625142A4 (en) * | 2010-10-05 | 2014-05-07 | Bio Works Technologies Ab | Method for removing arsenic from water using polymer based matrices with chelating groups comprising metal ions |
WO2024233291A3 (en) * | 2023-05-05 | 2024-12-19 | Bio-Rad Laboratories, Inc. | Multimodal chromatography resins with anionic and cationic ligands |
Also Published As
Publication number | Publication date |
---|---|
AU780286B2 (en) | 2005-03-10 |
JP2003531713A (en) | 2003-10-28 |
AU2507901A (en) | 2001-06-04 |
US7879244B1 (en) | 2011-02-01 |
EP1235748B1 (en) | 2011-07-20 |
EP1235749B1 (en) | 2011-01-19 |
CA2389515C (en) | 2012-08-28 |
US6702943B1 (en) | 2004-03-09 |
EP1235749A1 (en) | 2002-09-04 |
SE9904197D0 (en) | 1999-11-22 |
IL149783A (en) | 2005-11-20 |
JP5051957B2 (en) | 2012-10-17 |
AU782945B2 (en) | 2005-09-08 |
CA2389515A1 (en) | 2001-05-31 |
AU1704401A (en) | 2001-06-04 |
ATE517064T1 (en) | 2011-08-15 |
CA2392200A1 (en) | 2001-05-31 |
WO2001038227A3 (en) | 2001-11-15 |
DE60045558D1 (en) | 2011-03-03 |
IL149782A0 (en) | 2002-11-10 |
CA2392200C (en) | 2012-09-25 |
WO2001038228A1 (en) | 2001-05-31 |
IL149783A0 (en) | 2002-11-10 |
JP2003514664A (en) | 2003-04-22 |
ATE496007T1 (en) | 2011-02-15 |
WO2001038227A2 (en) | 2001-05-31 |
JP4814467B2 (en) | 2011-11-16 |
EP1235748A2 (en) | 2002-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6702943B1 (en) | Method for anion-exchange adsorption and anion-exchangers | |
AU2002235786B2 (en) | A method for mixed mode adsorption and mixed mode adsorbents | |
AU2002235786A1 (en) | A method for mixed mode adsorption and mixed mode adsorbents | |
US20110065900A1 (en) | Separation method utilizing polyallylamine ligands | |
JP2004516928A5 (en) | ||
EP1345694B1 (en) | A method for the manufacture of compositions containing low concentrations of salts | |
CA2412586C (en) | Adsorption method and ligands | |
AU2001283945A1 (en) | Adsorption method and ligands | |
US7320754B2 (en) | Method of preparing multi-modal anion-exchange ligands | |
CA2392374A1 (en) | A method for selective removal of a substance from samples containing compounds having nucleic acid structure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GE HEALTHCARE BIO-SCIENCES AB,SWEDEN Free format text: CHANGE OF NAME;ASSIGNORS:PHARMACIA FINE CHEMICALS AB;PHARMACIA LKB BIOTECHNOLOGY AB;PHARMACIA BIOTECH AB;AND OTHERS;SIGNING DATES FROM 19670125 TO 20011017;REEL/FRAME:017186/0644 Owner name: GE HEALTHCARE BIO-SCIENCES AB, SWEDEN Free format text: CHANGE OF NAME;ASSIGNORS:PHARMACIA FINE CHEMICALS AB;PHARMACIA LKB BIOTECHNOLOGY AB;PHARMACIA BIOTECH AB;AND OTHERS;SIGNING DATES FROM 19670125 TO 20011017;REEL/FRAME:017186/0644 Owner name: GE HEALTHCARE BIO-SCIENCES AB, SWEDEN Free format text: CHANGE OF NAME;ASSIGNORS:PHARMACIA FINE CHEMICALS AB;PHARMACIA LKB BIOTECHNOLOGY AB;PHARMACIA BIOTECH AB;AND OTHERS;REEL/FRAME:017186/0644;SIGNING DATES FROM 19670125 TO 20011017 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |